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The blood-brain barrier (BBB) is an important barrier that separates and protects the 
brain from the peripheral circulation. This BBB is formed by special tight junctions, a feature 
of the brain endothelium that is responsible for the BBB integrity and its low permeability. 
In several diseases, including Alzheimer’s disease (AD), BBB is impaired and changes in 
some important proteins are found. AD, the most common type of dementia, is characterized 
by an abnormal extracellular deposition of amyloid-β peptide (Aβ), which is believed to be 
a consequence of a failure in the balance between its production and clearance. Several 
molecules have been proposed as Aβ carriers and among them transthyretin (TTR) has been 
shown to have the capacity to bind and cleave Aβ, preventing its deposition and promoting 
its clearance, being considered as a neuroprotective protein. Moreover, previous reports 
highlighted the importance of TTR in the regulation of the expression of central nervous 
system (CNS) genes, pro-angiogenic genes in the eye and in the umbilical cord and blood-
brain barrier genes.  
In this project, we aimed at further investigating the participation of TTR in the brain 
vasculature, in biologic as in pathologic environments. 
In order to achieve our objectives, we began by evaluating the effect of TTR in the 
expression of tight junctions (TJs) - related genes, at the transcript and protein levels, using 
hCMEC/D3 cells. Our initial results obtained by qRT-PCR, using a PCR array kit, suggested 
that TTR was modifying the expression of several genes, but further individual qRT-PCR for 
the most affected genes did not confirm the PCR array results. Moreover, three other genes 
not evaluated in the PCR array, were assayed by qRT-PCR and no effect of TTR was 
detected. Next, we decided to advance to the analysis of gene expression at the protein level 
of two important TJs proteins, occludin (OCLN) and Claudin-3 (CLDN3), by 
immunocytochemistry. Here, we observed that also protein levels of these TJs were not 
altered by TTR, as seen at the transcript level. Altogether, our results suggest that TTR is not 
capable to modulate the gene expression of TJs-related genes. 
Furthermore, to evaluate the role of TTR in brain vessel angiogenesis, we examined 
the expression of genes known to be imported in angiogenesis, using two different 
endothelial cell lines, hCMEC/D3 and bEnd.3 cells. The qRT-PCR results showed that both 
cell lines presented similar transcript levels in the absence or presence of TTR variants, 
indicating that TTR presence also does not influence the expression of angiogenesis-related 
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genes. Additionally, using an in vitro wound healing assay, we investigated if the endothelial 
cell lines presented a different migration response, an important process of angiogenesis, 
when incubated in the presence or absence of TTR variants. However, the migratory response 
of the endothelial cells was similar in both conditions, as no significant differences were 
detected in the recovery of the wounded area in cells treated with TTR compared to control. 
These results supported our qRT-PCR results, demonstrating that TTR variants do not have 
a modulatory role on angiogenesis in the brain.  
Finally, we intended to understand if TTR is involved in the regulation of collagen 
IV levels in brain vessels. Using AD mice with different TTR backgrounds (TTR+/+, TTR+/- 
and TTR-/-), by immunohistochemistry, we showed that the collagen IV layer was increased 
in AD/TTR+/- and in AD/TTR-/-, as compared to AD/TTR+/+ animals. To further 
understand if TTR is directly responsible for this collagen IV alteration, we measured the 
collagen IV levels in non-transgenic mice with different TTR backgrounds. Here, we 
observed that collagen IV levels were similar in all animals, indicating that TTR is not 
directly responsible for the differences observed in the AD mice. Thus, we hypothesized that 
Aβ was the responsible for the increase of collagen IV levels in AD animals and, since TTR 
is capable of binding Aβ promoting its clearance, the differences in collagen IV measured in 
AD animals may result from an indirect action of TTR. In fact, incubation of bEnd.3 cells 
with Aβ species induced increased collagen IV which was counteracted by TTR, when co-
incubated with Aβ. TTR alone did not alter collagen IV in bEnd.3 cells, further corroborating 
our observations in the non-transgenic animals, and supporting the explanation that in AD 
mice, Aβ is responsible for the alterations in collagen IV layer and that TTR, indirectly, 
delays or partially avoids this alteration by sequestering the peptide, avoiding its aggregation 
and accumulation, and by enhancing its elimination from the brain. 
Previous results from our group also indicated that the protective effect of TTR on 
Aβ can be improved by stabilizing the tetrameric structure of this protein. With this in mind, 
also in a previous project, iododiflunisal (IDIF), a potent TTR stabilizer, was administrated 
to AD mice, resulting in cognitive improvement, as well as in decreased Aβ brain levels. To 
further investigate the relation between collagen IV levels and the protective role of TTR in 
AD, we now evaluated its levels in IDIF-treated and in control animals. Our results showed 
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that levels of collagen IV were decreased upon IDIF treatment, strengthening the stability 
hypothesis. 
Altogether, our results support a neuroprotective role for TTR in AD, mainly by 
acting directly on Aβ and avoiding, at least some of, the downstream events caused by this 
peptide. We showed that alterations at the vascular level, such as the thickness of the 
basement membrane, i.e. collagen type IV layer, can be prevented by TTR. Given that the 
vascular alterations are thought to be part of the initial alterations in AD, it is of the outmost 
importance to explore therapeutic strategies aiming at increasing TTR levels, known to be 
decreased in this disorder. 
 
Key concepts: Blood-brain barrier; Tight-Junctions, Angiogenesis, Alzheimer’s 
disease, amyloid-β peptide, Collagen IV, Transthyretin. 
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A barreira hemato-encefálica (BHE) é uma barreira essencial que tem como função 
separar e proteger o cérebro da circulação periférica. Esta barreira é conseguida através da 
existência de junções de oclusão, características do endotélio vascular cerebral, e que são 
responsáveis por manter tanto a integridade como a baixa permeabilidade da BHE. Em várias 
doenças, incluindo a doença de Alzheimer (DA), a BHE encontra-se comprometida, sendo 
possível detetar alterações em diversas proteínas importantes para o funcionamento desta 
barreira. A DA, o tipo de demência mais comum, é caracterizada por uma deposição 
extracelular anormal do péptido beta-amilóide (βA), pensando-se que esta deposição se deve 
a uma falha no balanço entre a produção e a remoção do péptido. Várias moléculas capazes 
de transportar βA têm sido propostas, entre elas a transtirretina (TTR), proteína capaz de ligar 
e clivar o βA, prevenindo a sua deposição e promovendo a sua remoção, atuando assim como 
uma proteína neuroprotetora. Para além desta sua capacidade, publicações anteriores 
sublinharam a importância da TTR na regulação da expressão de genes no sistema nervoso 
central, genes pró-angiogénicos no olho e no cordão umbilical e também de genes 
importantes para a BHE. 
 Neste projeto, o nosso objetivo foi investigar a participação da TTR a nível vascular 
no cérebro, tanto em condições fisiológicas como patológicas. 
 Para atingir este objetivo, começámos por avaliar o efeito da TTR na expressão de 
genes relacionados com as junções de oclusão, a nível da transcrição e tradução, utilizando a 
linha celular hCMEC/D3. Os nossos resultados obtidos inicialmente por reação em cadeia da 
polimerase em tempo real (RCP-TR), utilizando um kit contendo um painel de genes, sugeriu 
que a TTR estaria a alterar os níveis de expressão de diversos genes, mas após se realizar 
RCP-TR individuais para os genes mais alterados, os resultados do kit não foram 
confirmados. Além disso, três genes que não tinham sido avaliados no kit foram analisados 
individualmente, sendo que também não foram detetadas diferenças. De seguida, decidimos 
avançar para a análise dos níveis proteicos de duas junções de oclusão importantes, a ocludina 
e a claudina-3. Aqui, observámos que também os níveis proteicos destas duas junções de 
oclusão não sofreram alterações pela TTR, resultado idêntico ao que foi observado para os 
níveis de transcrição. Em suma, estes resultados sugerem que a TTR não é capaz de modular 
a expressão destes genes relacionados com as junções de oclusão. 
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 De seguida, para avaliar o papel da TTR no processo de angiogénese em vasos 
cerebrais, avaliámos a expressão de genes que promovem a angiogénese, usando duas linhas 
celulares diferentes, as hCMEC/D3 e as bEnd.3. Os resultados da RCP-TR demonstraram 
que, em ambas linhas celulares, os níveis de transcrição dos genes pró-angiogénicos 
mantiveram-se semelhantes na presença e ausência das variantes da TTR, indicando que a 
presença da TTR não influencia a expressão destes genes envolvidos na angiogénese. De 
seguida, utilizando o in vitro healing assay, investigámos se as linhas celulares apresentavam 
diferenças na sua capacidade de migração, um passo importante do processo de angiogénese, 
quando incubadas na presença ou na ausência das variantes da TTR. Os nossos resultados 
demonstraram que a migração das células foi semelhante em ambas condições, uma vez que 
não foram detetas diferenças no encerramento do golpe nas diferentes condições. Estes 
resultados, em conjunto com os obtidos nas RCP-TR, demonstram que as variantes da TTR 
não têm uma função moduladora do processo de angiogénese a nível cerebral. 
 Como último objetivo, pretendíamos perceber se a TTR poderia estar envolvida na 
regulação dos níveis de colagénio IV nos vasos cerebrais. Para isso, usando murganhos DA 
e com diferentes genótipos para a TTR (TTR+/+, TTR+/- e TTR-/-), demonstrámos por 
imunohistoquímica, que a camada de colagénio IV estava aumentada nos animais 
DA/TTR+/- e DA/TTR-/-, quando comparados com os animais DA/TTR+/+. De seguida, 
para perceber se a TTR estaria envolvida diretamente nestas alterações do nível de colagénio 
IV, quantificámos os níveis desta proteína em animais não-transgénicos com diferentes 
genótipos para a TTR. E, aqui, observámos que em ambos os genótipos, os níveis de 
colagénio IV eram semelhantes, indicando que a TTR não é diretamente responsável pelas 
diferenças observadas nos animais DA. Tendo em conta este resultado, colocámos a hipótese 
de que o βA poderia ser o responsável pelo aumento de colagénio IV nos animais DA e, uma 
vez que a TTR é capaz de ligar-se ao βA promovendo a sua remoção, as diferenças no nível 
de colagénio IV observadas nos animais DA podiam ser devido a esta sua ação no βA. E, de 
facto, ao incubar as células bEnd.3 com diferentes espécies de βA, observou-se um aumento 
de colagénio IV, aumento este contrariado quando βA e TTR foram incubados 
simultaneamente. Adicionalmente, quando as células foram incubadas só com TTR, os níveis 
de colagénio IV mantiveram-se inalterados, corroborando os resultados observados com os 
animais não transgénicos e apoiando a explicação de que nos animais DA, a TTR é 
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indiretamente responsável pelas alterações do colagénio IV, através da sua capacidade de 
sequestrar o βA, evitando não só a sua agregação e acumulação, como também por promover 
a sua eliminação do cérebro. 
 No nosso grupo, resultados anteriores indicaram que o efeito protetor da TTR no βA 
pode ser melhorado através da estabilização da sua estrutura tetramérica. Com isto em mente, 
também num projeto anterior, um potente estabilizador da TTR, o iododiflunisal (IDIF), foi 
administrado em animais DA, tendo originado melhorias cognitivas e uma diminuição dos 
níveis de βA no cérebro. Para investigar uma relação entre o colagénio IV e a função protetora 
da TTR na DA, avaliámos os níveis de colagénio IV em animais controlo e animais tratados 
com IDIF. Os resultados desta experiência demonstraram que após o tratamento com IDIF, 
os níveis de colagénio IV diminuíram, fortalecendo a importância da estabilização da TTR. 
 Em suma, os nossos resultados apoiam o papel neuroprotetor da TTR na DA, 
principalmente por atuar diretamente no βA, evitando assim as consequências negativas dos 
seus efeitos. Demonstrámos que alterações a nível vascular, tal como o aumento da espessura 
da membrana basal, especificamente da camada de colagénio IV, podem ser prevenidas pela 
TTR. Uma vez que se pensa que as alterações vasculares podem fazer parte das alterações 
que ocorrem inicialmente na DA, é extremamente importante explorar estratégias 
terapêuticas que tenham como objetivo aumentar os níveis de TTR, que se encontram 
diminuídas nesta doença. 
 
Conceitos chave: Barreira hemato-encefálica; Junções de oclusão; Angiogénese; 
Doença de Alzheimer; péptido beta-amilóide; colagénio IV; transtirretina 
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Thesis focus 
The main goal of this thesis is to explore the neuroprotective role of a specific protein, 
called transthyretin (TTR) in one of the most important networks of our brain, the brain 
vasculature, both in physiology and in pathology. The lack of previous studies on this 
relation, TTR-brain vasculature, was the initial motivation to start this work, and thus, the 
next section will provide an overview of relevant topics, introducing key concepts, for a 
better comprehension of the research project. 
 
1. Blood-Brain Barrier 
When we talk about the brain, the first thing that comes to our mind is the complexity 
of this organ, being active in every second. Although it accounts only for ≈ 2% of the body 
weight, the brain consumes a large amount of energy, requiring around 20% of an 
individual’s resting metabolic rate (Attwell and Laughlin 2001). To ensure that enough 
oxygen, glucose and other nutrients are adequately delivered to the brain, it is necessary a 
large blood vessel and microvessel network, being estimated that the total length of 
capillaries in the human brain is about 600 km, and the capillary surface area available for 
molecular transport is about 20 m2 (Begley and Brightman 2003). But this comes with a 
problem: despite the 
advantage of having this 
large network, undesirable 
compounds that could be 
toxic to the brain would be 
in higher concentrations, 
which is a problem since 
the brain is the most critical 
and sensitive organ in our 
body (Mahringer, Ott et al. 2014). However, our body is meticulously made, existing a 
special protection in the central nervous system (CNS) microvessels, the so called blood-
Figure 2. Schematic representation of the diffusion of a dye according to the 
injection place. (A) and (B) Results of Ehrlich and Goldman experiments, 
respectively. (C)  Assumption of the existence of an impermeable barrier between 
the CNS and the blood, and a permeable barrier between the brain and the CSF 
(Zlokovic 2008). 
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brain barrier (BBB), an exclusive anatomical and physiological barrier separating the CNS 
and the peripheral circulation. Its existance was firstly hypothezised after Paul Ehrlich has 
observed that a peripherally injected dye stained peripheral organs but not the brain and the 
spinal cord (figure 1) (Ehrlich 1885).  
Few years later, Goldman performed a staining experiment, similarly to Paul Ehrlich, 
injecting a dye directly into the cerebrospinal fluid (CSF), after which he observed that the 
brain and the CSF stained blue, but not the blood (Goldman 1913). These two experiments 
were essential for the suggestion of the existance of the BBB and, since these discoveries, 
new information about the BBB has been published for more than 100 years (figure 2).  
Figure 3. History of the blood-brain barrier research and discoveries (Mahringer, Ott et 
al. 2014). 
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The BBB is responsible for several roles, as controlling cerebral homeostasis, 
providing protection against toxic xenobiotics and pathogens (Weiss, Miller et al. 2009), 
mediating the efflux of waste products and restricting ionic and fluid movements between 
the blood and the brain (Abbott, Ronnback et al. 2006). 
A second “barrier” is formed by the epithelial cells of the choroid plexus, which 
constitute the blood-cerebrospinal fluid barrier (BCSFB). This one will not be explored, since 
it was not the focus of our work. 
 
1.1. Neurovascular Unit 
The blood-brain barrier exists primarily as a barrier constituted by the cerebral 
microvascular endothelium, a thin layer of simple cells called endothelial cells (ECs), which 
are significantly different from those in the periphery (Hawkins and Davis 2005). In close 
proximity to these brain ECs, other cells are indirectly involved in the development and 
maintenance of the BBB. All these cells together with the basal lamina, constitute the 
neurovascular unit (NVU). The first concept of NVU was introduced by Harder (Harder, 
Zhang et al. 2002), describing a relation between neurons, astrocytes and capillaries. These 
three types of cells, along with pericytes and basal membrane (BM), create the NVU.  
1.1.1. Endothelial cells 
Brain ECs are the primary element of the BBB, creating the walls of the capillaries, 
where a cerebral microvessel is enclosed by a single endothelial cell. These brain ECs are 
significantly different from non-brain ECs by: 
 Absence of fenestrations (Fenstermacher, Gross et al. 1988); 
 Presence of intercellular tight junctions (TJs) (Kniesel and Wolburg 2000); 
 Enhanced mitochondrial content, associated with a strong metabolic activity 
(Oldendorf, Cornford et al. 1977); 
 Low level of non-specific transcytosis (pinocytotic) (Sedlakova, Shivers et al. 
1999); 
 Prevented free exchange of solutes between blood and brain (Ohtsuki and 
Terasaki 2007). 
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All features together reveal the hallmark of the brain endothelium: a restrict and 
controlled permeability to plasmatic compounds and ions, protecting the brain from an 
imbalance in the homeostasis. Endothelial cells are one of the most important components of 
the NVU, being influenced by the others NVU’s cells/BM, as described next. 
 
1.1.2. Basal membrane 
Endothelial cells and pericytes are surrounded by the BM, which is constituted by 
laminin, collagen type IV, proteoglycans, fibronectin and other extracellular matrix proteins 
produced by both cell types of the NVU (Farkas and Luiten 2001). The BM contribution to 
the NVU was often underestimated, but it must be considered as an important part of the 
BBB regulation (Berzin, Zipser et al. 2000). Besides that, disruption of this extracellular 
matrix is associated with BBB breakdown and increase of its permeability (Rascher, 
Fischmann et al. 2002), since collagen IV is involved in the regulation of endothelial tight 
junction protein expression (Savettieri, Di Liegro et al. 2000). Moreover, collagen IV is 
capable of regulating angiogenesis, which will be discussed in the subchapter 1.4. 
1.1.3. Astrocytes 
Astrocytes are one of the glial cells that are present in the neurovascular unit. As can 
be seen in figure 3, these cells communicate with pericytes, neurons and capillary endothelial 
cells via their several foot processes (Abbott, Ronnback et al. 2006). It has been well 
documented the importance of astrocytes in the induction and maintenance of BBB integrity 
(Janzer and Raff 1987, Kuchler-Bopp, Delaunoy et al. 1999). When capillaries are co-
cultured with astrocytes, TJs (one of the most important feature in brain endothelial cells) are 
enhanced in length, width, and complexity, indicating a role in the formation and 
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configuration of these TJs (Tao-Cheng, Nagy et al. 1987). Also, astrocytes and endothelial 
cells are capable to communicate through calcium signals, influencing some aspects of the 
BBB functioning and transport, such as its permeability (Braet, Paemeleire et al. 2001). 
Moreover, astrocytes synthesize some biologically active molecules as the transforming 
growth factor-β (TGF-β), glial-derived neurotrophic factor (GDNF) and basic fibroblast 
growth factor (bFGF), which may influence endothelial cells (Wilhelm and Krizbai 2014). 
1.1.4. Pericytes 
Pericytes, also called Rouget cells after their discovery by Charles Rouget, are 
randomly distributed along the brain and non-brain microvessels, being surrounded (together 
with ECs) by the basal membrane composed of collagen type IV and other extracellular 
matrix proteins mentioned above (Bergers and Song 2005). These cells produce substances 
such as TGF-β, angiopoetin-1 and vascular endothelial growth factor (VEGF), influencing 
the endothelial function (Wilhelm and Krizbai 2014). Pericytes are important in the formation 
and maintenance of the BBB since it was shown that pericytes deficiency leads to an increase 
in the permeability of the BBB (Armulik, Genove et al. 2010), endothelial hyperplasia and 
abnormal vascular morphogenesis (Hellstrom, Gerhardt et al. 2001). Moreover, the integrity 
of the wall of the capillaries is compromised by the loss of pericytes (Lindahl, Johansson et 
al. 1997). It was also shown that pericytes are modulators of blood flow (Peppiatt, Howarth 
Figure 4. Representation of the neurovascular unit. The BBB is composed 
by microvessel endothelial cells which are surrounded by pericytes, astrocytes 
end-feet, neurons and the basal lamina, all essential for the development and 
maintenance of the BBB (Heye, Culling et al. 2014). 
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et al. 2006) and pericytes-derived angiopoietin-1 induces TJs expression, specifically 
occludin, confirming that pericytes influence positively the maintenance of BBB (Hori, 
Ohtsuki et al. 2004). 
1.2. Junctional complexes at the BBB 
As mentioned above, one of the main roles of the BBB is to act as physical barrier, 
separating the brain from the blood, with a restricted paracellular diffusion and a low 
permeability across the endothelium. This feature is accomplished by a network of 
interendothelial junctions as TJs, adherens junctions (AJs) and gap junctions (when present) 
– figure 4 (Bazzoni and Dejana 2004). 
 
1.2.1. Tight junctions, adherens junctions and associated proteins 
TJs in the brain ECs are very similar to epithelial TJs. In this group we can find a 
large amount of proteins involved, but it is possible to highlight three major transmembrane 
proteins (or families): occludin (OCLN), claudins (CLDNs) and junction associated 
molecules (JAMs). Linked to these proteins we can find different cytoplasmic proteins as 
Figure 5. Representation of the interendothelial junctions 
network. Adjacent endothelial cells are connected by different 
TJs, AJs and GJs (De Bock, Vandenbroucke et al. 2014). 
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zonula occludens (ZO) family, vinculin and cingulin which are in contact with 
transmembrane proteins and to the actin cytoskeleton, creating a multi-protein complex 
(Wolburg and Lippoldt 2002).  
The first transmembrane protein identified, firstly in chickens (Furuse, Hirase et al. 
1993) and then in mammals (Ando-Akatsuka, Saitou et al. 1996), was OCLN, a 65 kDa 
protein with four transmembrane domains, whose expression is developmentally regulated. 
OCLN is highly expressed in the brain endothelium but less (or even absent) in non-neural 
endothelial cells (Daneman, Zhou et al. 2010). In OCLN deficient mice, TJs are 
morphologically indistinguishable from the wild-type (wt) controls, indicating that OCLN is 
not so important for TJs formation (Saitou, Furuse et al. 2000). But, other studies have shown 
the opposite (Balda, Whitney et al. 1996, Wong and Gumbiner 1997). Still associated with 
this role, OCLN seems to be an important protein that can alter paracellular permeability 
(Hirase, Staddon et al. 1997). This protein is mostly associated with the TJ formation but its 
functions are not limited to this role. As example, OCLN can be involved in epithelial 
differentiation (Schulzke, Gitter et al. 2005). 
With molecular weighs between 20-34 kDa, the CLDN family is constituted by more 
than 22 members that can be found in different tissues, but only a few are expressed at the 
BBB (Mahringer, Ott et al. 2014). These are important for the formation and maintenance of 
the BBB, and their breakdown lead to the disruption of the BBB. In CLDN-5 deficient mice 
(CLDN5-/- mice), molecules with <800 Da were capable to cross the BBB, even if the 
development and morphology of blood vessels were not compromised (Nitta, Hata et al. 
2003). Moreover, in the same study, CLDN5 downregulation was shown to be related with 
BBB breakdown via VEGF, although reversible when recombinant CLDN5 was expressed, 
leading to the rescue of low paracellular permeability and thus, decreasing the BBB 
breakdown (Argaw, Gurfein et al. 2009). 
The other relevant TJs involved in the BBB integrity are the JAM family. There are 
three known JAMs: JAM-A, JAM-B and JAM-C (or JAM-1, JAM-2 and JAM-3, 
respectively). These proteins are present in endothelial and epithelial cells, leukocytes, 
platelets and erythrocytes (Mandell and Parkos 2005). JAM proteins are involved in different 
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processes, including the regulation of tight junction assembling (Liu, Nusrat et al. 2000) and 
angiogenesis signaling (Naik, Mousa et al. 2003). 
As a part of the junctional complex, it is possible to find other proteins at cell-cell 
junctions, forming adhesive contacts between cells, the so called adherens junctions (also 
known as zonula adherens). The AJs complex are mainly composed by the interaction of the 
cadherin protein family, such E-cadherin and vascular endothelial (VE)-cadherin, and the 
catenin family including β-catenin, α-catenin and p-120-catenin, which interact with actin 
(Hartsock and Nelson 2008). Similar to TJs, these proteins are important for the BBB 
integrity and to reduce its permeability (Corada, Mariotti et al. 1999, Navaratna, McGuire et 
al. 2007). VE-cadherin, besides its role as a tight connection between cells, is also associated 
with processes like angiogenesis (Wallez, Vilgrain et al. 2006) and cell proliferation (Caveda, 
Martin-Padura et al. 1996). 
Equally important, transmembrane proteins are associated with cytosolic proteins, 
some already mentioned above: ZO family, cingulin, vinculin. ZO-1, probably one of the 
most studied proteins, was shown to be involved in cell-cell tension, angiogenesis, barrier 
formation (Tornavaca, Chia et al. 2015), and its dissociation is followed by an increase of 
permeability (Abbruscato, Lopez et al. 2002). Actin is also an important component of this 
junctional complex. It permits the anchorage of transmembrane proteins (using intermediated 
proteins) to the actin cytoskeleton, essential for the barrier stability/permeability and cell 
movement (Lai and Kuo 2005, Dejana, Tournier-Lasserve et al. 2009). 
Altogether, we can say that a complex network of proteins is vital for the formation 
and maintenance of BBB, with innumerous functions, and the failure of one part might be 
enough to compromise this important barrier. 
1.3. Transport at BBB 
The transport across the BBB is very controlled, since the maintenance of the 
homeostasis is crucial for the brain, which is achieved through numerous mechanisms, 
depending on the nature of the substance crossing the barrier (figure 5). These include 
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transmembrane diffusion, saturable transporters, receptor-mediated transcytosis and 
adsortive transcytosis (Banks 2009). 
Due to its tight barrier properties, only a few small polar compounds are able to cross 
the BBB via diffusion across TJs (paracellular transport), including urea and water, since 
almost no space exists between adjacent cells. 
The main type of transport is the transmembrane diffusion (or passive diffusion) 
(Oldendorf 1974), where molecules can enter inside endothelial cells via a non-saturable 
mechanism, simply depending on the capacity of the compound to melt into the cell 
membrane. Small and lipophilic molecules can easily cross the cell membrane, but other 
factors as charge and tertiary structure also affect this type of transport (Banks 2009). Despite 
the ability of these molecules to cross the luminal cell membrane, not all will reach the brain. 
In fact, to regulate passive transport into the brain, endothelial cells have efflux pumps that 
are responsible to return many unwanted molecules back to the blood (Wong, Ye et al. 2013). 
This return is made by the ATP-binding cassette tranporters (ABC). At the BBB, the most 
important ABC transporters for efflux transport are the P-glycoprotein (Pgp), the multidrug 
resistance-associated proteins and breast cancer resistance protein (Abbott, Patabendige et 
al. 2010) which remove potentially neurotoxic endogenous or xenobiotic molecules from the 
Figure 6. Scheme of transport mechanisms across the BBB, depending on the compound nature 
(Abbott, Ronnback et al. 2006). 
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brain, protecting and detoxifying this organ (Dallas, Miller et al. 2006). Oxygen and carbon 
dioxide are examples of molecules using passive diffusion as the way of crossing the BBB. 
Another way for compounds to reach the brain is via carrier-mediated transport. 
Essential compounds, such as glucose, aminoacids and nucleosides, can enter in the brain 
using specific transporters. The most common transporter belong to  the solute carrier 
proteins (SLC) family. SLC2A1, more known as glucose transporter-1 (GLUT1), is 
responsible for the facilitation of glucose transport, following its concentration gradient 
(Hediger, Romero et al. 2004). Other transporters from the SLC family are involved, such as 
the monocarboxylate transporters, which transport short-chain monocarboxylic acids (as 
lactate and pyruvate), and the SLC7 which transport cationic aminoacids (arginine, lysin and 
ornithine) (Mahringer, Ott et al. 2014). These transporters are crucial for the brain activity 
since it requires a lot of energy to work, thus, it also needs these metabolic substrates 
(specially glucose). Ions transporters, such as sodium pump and sodium-hydrogen 
exchanger, are other type of transporters that are essential for the maintenance and regulation 
of intracellular pH in the endothelium (Taylor, Nicola et al. 2006).  
Proteins and peptides are solutes with a large size and mass and cannot cross the 
endothelium by passive transport. These molecules reach the brain via vesicular transport 
across BBB – transcytosis. Two ways of transcytosis can occur: either by specific receptor-
mediated transcytosis or nonspecific adsorptive-mediated transcytosis (AMT). The first one 
is made by specific interaction between the molecules and receptors localized on ECs 
membrane. Proteins as insulin, leptin and transferrin are examples of proteins transported 
using this way (Pardridge 2003, Herve, Ghinea et al. 2008). In the AMT, positively charged 
peptides in the blood interact with the negatively charged phospholipid head groups of the 
cell membrane, inducing membrane invagination and vesicle formation. After entering the 
intracellular space, vesicles fuse with the abluminal side of endothelium and are released to 
the brain. Briefly, it consists in an elctrostatic interaction between molecules and cell 
membrane (Jones and Polt 2015). 
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1.4. Development of new vessels 
The development of blood vessels can be made via two different processes: 
angiogenesis and vasculogenesis. In the last one, blood vessels have as origin the 
differentiation of hemangiogenic stem cells and angioblasts from pluripotent mesenchymal 
cells (Demir, Kayisli et al. 2006). Angiogenesis, the formation of vessel branches from pre-
existing vessels, is the predominantly process of blood vessel formation in the brain (Lee, 
Han et al. 2009). This process can be subdived in sprouting angiogenesis and intussusceptive 
angiogenesis (Burri and Tarek 1990). Sprouting angiogenesis is the most studied type of 
angiogenesis and is composed by different steps: enzymatic degradation of capillary 
basement membrane, EC proliferation and migration followed by their arrangement in a tube 
formation, and vascular stabilization through the establishment of new basement membrane 
and specialized cells attachment (figure 6) (Risau 1997, Adair and Montani 2010).  
In more detail, the beginning of blood vessels formation starts with the degradation 
of the BM by enzymes secreted by activated ECs, leading to the creation of little holes in the 
BM. At this point, these ECs begin to proliferate at a higher rate, and they migrate out through 
the holes in the BM (Conway, Collen et al. 2001). During that, the tissue in front and around 
the sprouting vessel is remolded by metalloproteinases, allowing the vessel to extend and to 
form a tubular structure. To finalize, if the new blood vessel contacts with another existing 
vessel, it will be stabilized by surrounding of a new BM and the presence of specialized cells, 
Figure 7. Overview of sprouting angiogenesis (Adair and Montani 2010). 
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such as smooth muscle cells and pericytes. Both together provide structural support for the 
vessel functioning (Zakrzewicz, Secomb et al. 2002, Pandya, Dhalla et al. 2006).  
Angiogenesis is highly regulated by the presence of anti-angiogenic and pro-
angiogenic factors, allowing to maintain an important balance (figure 7). But, in response to 
several signals, this balance can be altered, both in physiological and pathological conditions. 
Physiologically, alterations in the microvessel network are necessary in different 
processes, including wound healing, exercise and tissue growth (Pries and Secomb 2014). In 
pathological conditions, angiogenesis can be found up-regulated or down-regulated, 
depending on the proportion of anti- and pro-angiogenic factors. Up-regulation of 
angiogenesis can be found in several diseases such as cancer, atherosclerosis and diabetic 
retinopathy (Folkman 1995), while down-regulation is an important causal factor for 
coronary artery disease, cardiac failure and tissue failure (Pandya, Dhalla et al. 2006). 
Hypoxia, the deprivation of adequate oxygen supply, is an important promoter of 
angiogenesis. This deficiency of oxygen leads to an increase of pro-angiogenic factors  
(Hirota and Semenza 2006). bFGF, VEGF and its receptors, angiopoietins (ANGPTs) and 
transforming growth factor beta 2 (TGFB2) are examples of these pro-angiogenic factors 
Figure 8. Angiogenesis regulation. Balance between 
activation and inhibition of angiogenesis is highly 
regulated by several stimulatory and inhibitory factors 
in response of several physiological and pathological 
conditions (Zetter 2008) 
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(Shibuya 2011, Dulloo, Phang et al. 2015). It is important to refer that both type of angiogenic 
factors are able to affect one or more angiogenic steps, but mainly acting on EC 
proliferation/migration and on the BM and extracellular matrix (ECM). 
1.4.1. Extracellular Matrix functions during Angiogenesis  
The ECM is a key component for each step of angiogenesis, providing structural 
support and also molecular signals that are essential for blood vessel formation. To start 
angiogenesis, it is required EC activation and proliferation, which is achieved due the action 
of angiogenic cytokines and EC adhesion to ECM through integrins, since for an efficient 
cytokine activation, is necessary the presence of integrins (Giancotti and Ruoslahti 1999). 
Thus, without the presence of ECM, EC activation and proliferation ceases and angiogenesis 
doesn’t occur. Moreover, also EC migration requires adhesion to ECM (Ausprunk and 
Folkman 1977). Relatively to new blood vessels morphogenesis, ECM are capable to regulate 
EC shape and morphogenesis. Studies showed that collagen I is capable to alter ECs 
morphology and to make them align into cords similarly to those observed during 
angiogenesis in vivo (Whelan and Senger 2003), and also capable of induce and support 
lumen formation by ECs (Senger and Davis 2011). 
1.4.1.1 Collagen IV as a player in angiogenesis 
As seen above, the ECM and the BM are important for angiogenesis process. Collagen 
IV, the predominant protein in the BM, can have different functions in this process. Studies 
have shown that synthesis and deposition of Collagen IV is indispensable for vascular 
survival and maturation. Bonanno and colleagues studied the angiogenic response of native 
ECs in three-dimensional vascular organ culture, culturing rings of rat aorta in the absence 
or presence of collagen IV, and reported that collagen IV increased the vascular elongation, 
survival and stabilization, in a dose-dependent manner (Bonanno, Iurlaro et al. 2000). In 
another study, inhibition of collagen production led to a marked anti-angiogenic effect 
(Nicosia, Belser et al. 1991). In Bahramsoltani and colleagues work, they showed the 
expression of collagen IV in four different microvascular endothelial cell types, two of them 
classified as angiogenic and the other two as non-angiogenic. Curiously, secretion and 
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deposition of collagen IV was only observed in the two angiogenic cultures, suggesting that 
angiogenesis is dependent on collagen IV deposition (Bahramsoltani, Slosarek et al. 2014). 
However, during the ECM remodeling, collagen IV is degraded, generating small anti-
angiogenesis molecules from its α chains, such as arresten, canstatin and tumstatin (Mundel 
and Kalluri 2007). These molecules are endogenous angiogenesis inhibitors which are 
involved in the balance between pro- and anti-angiogenic factors (Mundel and Kalluri 2007). 
2. Alzheimer’s Disease 
Alzheimer’s disease (AD), name given in tribute to the first person that describe it, is 
a chronic neurodegenerative disease, comprising the major cases of dementia worldwide, that 
usually affects the older people (age >65 years). The greatest risk factor for AD is age and is 
characterized by a progressive loss of cognitive functions (such as memory and language) 
(Burns and Iliffe 2009). The World Alzheimer Report 2016 estimated that there were 46.8 
million people worldwide with dementia and this number can reach to 131.5 million in 2050 
(International, 2016). Despite of being intensively studied, the etiological mechanisms 
underlying the neuropathological changes remain unclear, but being suggested that is 
probably caused by a set of genetic and environmental factors (Reitz and Mayeux 2014). 
 
2.1. Genetics behind Alzheimer’s disease 
 The majority of patients only develop clinical symptoms at age older than 65 years – 
called late-onset AD or sporadic AD – , but for 2 to 10% of patients the symptoms appear 
earlier – early-onset AD or autosomal dominant familial AD (FAD) (Van Cauwenberghe, 
Van Broeckhoven et al. 2016). During a long time, genetic factors contributing to the disease 
were searched, being discovered several mutations that are capable of triggering the disease. 
It was found that three important genes are involved as a cause of autosomal dominant 
familial AD when mutated (originating early-onset AD cases), namely amyloid precursor 
protein (APP), Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2) (Bertram, Lill et al. 2010), 
all three genes encoding proteins linked to APP. PSEN1 and PSEN2, members of the same 
family, are essential components of the γ-secretase complex responsible for cleavage and 
release of amyloid-β peptide (Aβ). Thus, mutations in these genes interfere with APP 
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processing and Aβ production (described below). Opposite to FAD, sporadic AD does not 
show autosomal-dominant inheritance. Instead, multiple genetic and environment risk factors 
may be involved. One of the genes associated with sporadic AD is the ε4 allele of the 
apolipoprotein E (APOE) gene, localized on chromossome 19q13. APOE gene can have three 
different polymorphic alleles - ε2, ε3 and ε4 – which have a worldwide frequency of 8.4%, 
77.9% and 13,7% respectively (Liu, Liu et al. 2013), but in AD patients, the frequency of the 
ε4 allele is about 40% (Bu 2009). Thus, patients who carry APOE ε4 allele are at higher risk 
to develop AD when compared with noncarriers, but this allele per si is not a determinant of 
the disease (Schmidt, Carlo et al. 2014). Interestingly, on the other hand, it was shown that 
ε2 allele could have a protective effect in late-onset AD (Corder, Saunders et al. 1994). 
2.2. Pathophysiology of Alzheimer’s disease 
2.2.1. Neuropathology 
In the description of the first case of AD, some typical features were found, both 
macroscopic and microscopic features. Macroscopically, in the brains obtained from patients 
with AD, it is possible to identify a clear cerebral cortical atrophy, specially in the primary 
motor, sensory and visual areas. Also, a symmetrical dilation of the lateral ventricles 
(hydrocephalus ex vacuo) is observed, caused by a encephalic volume loss (Perl 2010). 
Although these changes are associated with AD, they may also be present in the brains of 
elder persons without AD, the difference being the extent and distribution of the changes, 
which are increased in AD patients (Terry 1986). Microscopically, AD is characterized by 
the presence of extracellular aggregated Aβ peptide constituting the senile plaques (SP), and 
intracellular aggregates of hyperphosphorylated tau protein creating the neurofibrillary 
tangles (NFTs) (figure 8)  (Tiraboschi, Hansen et al. 2004, Kolarova, Garcia-Sierra et al. 
2012).    
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2.2.1.1. Neurofibrillary tangles 
When Alois Alzheimer described the first case of AD, he noted the presence of some 
abnormal fibrils inclusions inside cells, now known to be the neurofibrillary tangles. The 
NFTs are composed of abnormal fibrils with around 10nm in diameter that occur in pairs and 
are twisted in a helical fashion with a regular periodicity of 80nm (Perl 2010). These NFTs 
are mainly constituted by the microtubule-associated protein tau which presents an abnormal 
hyperphosphorylation (Lee, Balin et al. 1991), but it is possible to find other proteins, such 
as ubiquitin (Perry, Friedman et al. 1987) and cholinesterases (Mesulam and Asuncion Moran 
1987). Relatively to NFTs distribution, it is possible to find them in the layer II neurons of 
the entorhinal cortex, the CA1 and subicular regions of the hippocampus, the amygdala, and 
the deeper layers (layers III, V, and superficial VI) of the neocortex (Morrison and Hof 1997). 
Tau is a cytosolic protein whose physiologic function is the promotion of the assembly of 
tubulin into microtubules and its stabilization (Weingarten, Lockwood et al. 1975). 
Moreover, tau is involved in more than 20 clinicopathological entities, besides AD (Williams 
2006). The process which leads to hyperphosphorylation of tau is unclear, but studies suggest 
to be a consequence of an upregulation of tau kinase or a downregulation of tau phosphatase. 
Furthermore, these abnormal tau phosphorylations modulate tau aggregation by disrupting 
its binding to microtubules and leading to its aggregation, resulting in the increase of soluble 
tau. Next, soluble tau dimerize and forms oligomers. In the end, oligomers originate 
protomers which will form paired helical filaments and NFTs (figure 9) (Martin, Latypova 
et al. 2011). 
Figure 9. Representation of microscopic hallmarks of AD. (a) Senile plaques and (b) neurofibrillary 
tangles (Aguzzi and O'Connor 2010). 
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2.2.1.2. Senile Plaques  
Senile plaques, also called neuritic plaques, are extracellular amyloid deposits found 
in the brain of AD patients, but it is also possible to find in normal aging, being mostly 
constituted by Aβ (Cras, Kawai et al. 1991). These plaques present a variable morphology 
and size, and are located specifically in the hippocampus and the cortex (Costa, Ferreira-da-
Silva et al. 2008). Also, it is possible to divide amyloid plaques in different subtypes 
Figure 10. Representation of NFTs formation
(Martin, Latypova et al. 2011). 
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depending on the morphology, including diffuse SP (pre-amyloid), primitive SP (neuritic), 
classic SP (dense-core) and compact SP (burnt-out) (Armstrong 2009). The last subtype is 
characterized by an increase of neurite curvature and dytrophic neurites (axons and 
dendrites), synaptic loss, neuron loss, and recruitment and activation of both astrocytes and 
microglial cells (Serrano-Pozo, Frosch et al. 2011). 
2.3. Biochemistry of Aβ 
As referred above, Aβ is the major component of senile plaques in AD. With 
approximately 4 kDa, Aβ is a small peptide originated by proteolytic processing of APP, a 
type I transmembrane protein essential for normal brain (Shariati and De Strooper 2013), 
where the region that corresponds to the Aβ includes the exon 16 and 17 of APP. Aβ was 
first isolated and sequenced by Glenner and Wong (Glenner and Wong 1984), and is found 
in the plasma, brain and CSF. Despite being always associated with its negative effect in AD, 
Aβ has been linked with several physiological functions such as ion channel modulation 
(Plant, Webster et al. 2006), regulation of cholesterol transport (Yao and Papadopoulos 2002) 
and more recently suggested as an antimicrobial peptide (Kumar, Choi et al. 2016).  
APP is a protein abundantly expressed in the brain but is possible to find it in other 
tissues. The gene codifying for APP is located in the chromosome 21 in humans, and contains 
18 exons (Zheng and Koo 2011). Interestingly, since APP gene duplication alone is capable 
to cause early-onset AD with cerebral amyloid angiopathy, it explains the increased risk for 
Down’s syndrome (trisomy 21) patients to develop AD (Thinakaran and Koo 2008). APP 
processing can occur in two different ways: the non-amyloidogenic pathway and the 
amyloidogenic pathway, being Aβ produced by the later (figure 10). 
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2.3.1. APP processing: non-amyloidogenic and amyloidogenic 
pathways 
Depending on the proteolysis pathway, APP can originate different peptides which 
have different functions. In the non-amyloidogenic pathway, two enzymes are responsible 
for the cleavage of APP. Firstly, α-secretase, an enzyme of the ADAM family (Rossner 
2004), cuts the peptide bond between the Lys687-Leu688 of APP770, within the residues 16 
and 17 of Aβ sequence, abolishing its production (Esch, Keim et al. 1990). This cleavage 
originates a large soluble fragment (sAPPα, ~100kDa) and a carboxyl-terminal fragment 
(CTF83, ~10kDa). The following cleavage is made by γ-secretase which cuts the CTF83, 
generating the p3 peptide and an APP intracellular domain (AICD, ~6kDA) fragment 
(Multhaup, Huber et al. 2015). Importantly, all peptides resulting from both cleavages are 
non-amyloidogenic. Also relevant, γ-secretase is a complex of four proteins, where the 
PSEN1 and PSEN2 are involved. Mutations in the genes coding these two proteins lead to 
an increase of Aβ production (enhances Aβ42 production compared to Aβ40), being one of 
the explications for the importance of these mutations being a cause of early-onset AD. 
In a very similar process, in the amyloidogenic pathway, APP is also cleaved by two 
enzymes. Here, the difference is in the enzyme responsible for the first cut, the β-secretase 
instead of the α-secretase, generating the soluble ectodomain sAPPβ and the CTF99 fragment 
after the cleavage (Zhang, Thompson et al. 2011). The CTF99 fragment is then cleaved by 
Figure 11. Representation of APP processing. The transmembrane APP can be processed 
by two different pathways: in the left it is represented the amyloidogenic pathway and in the 
right the non-amyloidogenic pathway (Pajak, Kania et al. 2016). 
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the γ-secretase, releasing the AICD fragment and the Aβ peptide (Multhaup, Huber et al. 
2015). This Aβ peptide can have different sizes and, consequently, it has different propensity 
to oligomerize and form the amyloid plaques (Haass and Selkoe 2007). But, it needs to be 
clear that APP processing occurs in the normal cellular metabolism through life, being 
possibly to find Aβ and NFTs in the brain of non-AD elderly people (Terry 1986). But then, 
how Aβ is related as a cause of AD?  
2.3.2. Amyloid cascade hypothesis 
 The etiology of AD is still unclear, and different theories try to explain this 
disorder, all based in different molecular mechanisms to back them up, but not absolutely 
consistents.  
Among these theories, the “amyloid cascade hypothesis” is the most known and 
stronger. It was formalized by Hardy and Higgins (Hardy and Higgins 1992). The beginning 
of this cascade is when changes in Aβ metabolism occur, such as increase in total Aβ 
production, increase in the Aβ42 specie compared to Aβ40, since the first is more toxic, or 
reduction in Aβ degradation/clearance (Selkoe 1991). Then, Aβ assembly occurs (figure 11), 
starting with its oligomerization and formation of non-fibrillar deposits. These oligomers are 
already capable to do severe changes in synaptic function, leading to neuronal dysfunction. 
In fact, soluble Aβ oligomers represent the most toxic form of this protein (Kumar and Walter 
2011). Over time, the non-fibrillar deposits evolve to Aβ fibrils, and several negative events 
occur: local inflammatory responses (as microgliosis and astrocytosis), synaptic spine loss, 
neuritic dystrophy, oxidative stress and altered ionic homeostasis. Finally, oligomerization 
and hyperphosphorylation of tau is observed. All changes together lead to a widespread 
neuronal dysfunction, cell dead and culminates in dementia with senile plaques and NFTs 
Figure 12. Representation of Aβ assembly. Adapted from (Kumar and Walter 2011). 
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(Haass and Selkoe 2007). Nevertheless, this hypothesis is not accepted by everyone, since 
the accumulation of new studies show data contradicting this theory. For example, it was 
shown a poor correlation between the degree of deposition and the degree of dementia in AD 
patients. It was also observed that some mouse models of AD show behavioral deficits prior 
to amyloid deposition (Pimplikar 2009). 
All together, it is clear that the pathogenesis of AD is a complex process and several 
factors are involved, and it can not be explained by a single theory. 
2.3.3. Aβ clearance 
It is known that in the brains of AD patients, Aβ is highly present, but how it happens 
if the majority of patients with sporadic AD do not present an increase of Aβ production? 
The unbalance between Aβ production and clearance is determinant for Aβ accumulation. 
Since dysfunction in its clearance is crucial in this process, it is also important to understand 
the mechanisms behind it (Wang, Zhou et al. 2006). 
The clearance of Aβ from the brain can occur by different pathways: receptor-
mediated transport across the BBB, enzyme-mediated degradation and anti-Aβ 
autoantibodies. 
The transport of Aβ across the BBB is possible to happen in both direction: brain-to-
blood and blood-to-brain. From the brain to the blood, it can be removed via interstitial fluid 
bulk flow into the bloodstream (Crossgrove, Li et al. 2005) or be transported across the BBB 
via receptor mediated, the principal mechanism of Aβ transport across this barrier. Moreover, 
removal of Aβ via interstitial fluid occurs very slowly and it is responsible for the clearance 
of only 10-15% of the total brain Aβ (Wang, Zhou et al. 2006). 
During receptor-mediate brain efflux across the BBB, Aβ removal starts with its 
binding to the Low-density lipoprotein receptor-related protein 1 (LRP1) at the abluminal 
side of the endothelial membrane, crossing the BBB by endocytosis or transcytosis, and 
reaching the blood. There, the free Aβ circulating in the blood is sequestered by soluble LRP 
(sLRP) and guided to its degradation organs, the liver and the kidney (systemic clearance) 
(Bell and Zlokovic 2009). In addition to LRP1, other transporters are involved in efflux of 
Aβ, such as LRP2 (also called megalin) and P-gp (Jeynes and Provias 2013). 
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As said before, Aβ can also enter in the brain from the periphery via receptor-
mediated transport. Here, the receptor for advanced glycation end products (RAGE) is the 
major “helper”, being located on the luminal membrane of the endothelium. 
In conclusion, the balance between influx and efflux of Aβ, mediated by LRP1/2 and 
P-gp or RAGE, is important to maintain a reasonable Aβ level in the brain. Alterations on 
the levels of these receptors is enough to lead to an impaired clearance of Aβ and 
consequently, to all the negative effects expected in the amyloid cascade hypothesis.  
2.4. BBB dysfunction and AD 
In several diseases, such as AD, BBB dysfunction has been described as an important 
part in both early and late steps of disease progression (Weiss, Miller et al. 2009). In fact, 
important features of the BBB described here are negatively altered, contributing for the 
exacerbation of the AD (figure 12). 
First, numerous studies demonstrated that Aβ is capable to decrease the levels of tight 
junction proteins and, consequently, increase the permeability of BBB (Tai, Holloway et al. 
2010, Kook, Hong et al. 2012).  
Several alterations are also observed in the Aβ influx and efflux, mostly due to 
alterations in the levels of the transporters. LRP1, the major mediator of Aβ efflux, was 
Figure 13. Alterations leading to BBB dysfunction 
in aging and in AD (Marques, Sousa et al. 2013). 
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demonstrated to be decreased in AD (Shibata, Yamada et al. 2000). Moreover, it was shown 
that P-gp, the other protein involved in Aβ efflux is lower in AD (Vogelgesang, Cascorbi et 
al. 2002, Wijesuriya, Bullock et al. 2010). On the other hand, several studies showed that 
RAGE is found to be upregulated in AD (Srikanth, Maczurek et al. 2011). All together, these 
alterations contribute to decreased Aβ efflux and increased influx, and consequently to 
disease progression.  
Other alterations can be found, such as accumulation of extracellular matrix 
components and stiffening of the vessel wall, increased pinocytotic vesicles and decrease of 
endothelial mitochondrial density (Marques, Sousa et al. 2013). 
 
2.4.1. Cerebral amyloid angiopathy – Aβ type 
Cerebral amyloid angiopathy (CAA) is a disorder caused by the accumulation of 
amyloid in the walls of the brain’s blood vessels, being classified according to the amyloid 
protein involved (Yamada 2015). The most common form of CAA is the accumulation of Aβ 
(figure 13), and it is commonly found in brains of AD patients and also in elder brains without 
AD (Vinters 1987), however CAA can be an independent pathogenic factor contributing to 
dementia. Similar to AD, the prevalence of CAA increases with age, and mutations in the 
APP gene are associated with this disease. Some studies suggested that Aβ found in vessels 
is derived from the brain cells, being transported through periarterial interstitial fluid drainage 
pathways until reach the blood vessels for its clearance (Weller, Massey et al. 1998). Since 
the mechanism of clearance is compromised, Aβ starts to progressively accumulate.  
Figure 14. Representation of brain’s blood vessels in CAA. Deposits of amyloid are observed (a) using histological 
Congo red staining, using polarized light and (b) immunohistochemistry against Aβ (Tanskanen, Makela et al. 2012) 
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Aβ accumulation can also result from an increase of the BM in vessels: the thickness 
of the BM can lead to a formation of a barrier, preventing Aβ to reach the blood. Thus, Aβ 
slowly accumulates, creating all the negative effects already described. Moreover, it is known 
that Aβ has affinity to proteoglycans present in the BM (Snow, Kinsella et al. 1995, Weller, 
Massey et al. 2000). The presence of these proteoglycans in the BM might sequester Aβ from 
the interstitial fluid, leading also to accumulation of Aβ (Tian, Shi et al. 2006). Alterations 
in the BM are present in AD and CAA and, in fact, several studies evaluated the levels of 
collagen IV in AD brains. In most of the studies performed with mice, it was observed an 
increase in collagen IV in AD brain vessels compared to control littermates (Bourasset, 
Ouellet et al. 2009, Mehta, Short et al. 2013). Moreover, similar results were obtained when 
comparing human brains of AD patients with controls (Kalaria and Pax 1995, Lepelletier, 
Mann et al. 2017). Interstingly, aging is also associated with increased collagen IV content 
in human microvessels (Uspenskaia, Liebetrau et al. 2004). This last result is specially 
important, since CAA can occur in elder brains without AD. 
 
3. Transthyretin 
3.1. TTR – Structure and functions 
TTR, previously called prealbumin due to the ability to migrate slightly faster than 
albumin on an electrophoresis of a plasma sample, is a protein mainly synthesized in the liver 
and in the choroid plexus, being secreted into the bloodstream and the CSF, respectively 
(Soprano, Herbert et al. 1985). The TTR gene is localized in the chromosome 18 (Wallace, 
Naylor et al. 1985) and codifies for the TTR-monomer originating a polypeptide with 147 
aminoacids. TTR is a homotetrameric protein, having four identical subunits assembled, 
originating a protein with ~55 kDa (Kanda, Goodman et al. 1974). It is possible to find TTR 
(or a homologous protein) in many species, including mammals, birds, reptiles and 
amphibians (Schreiber and Richardson 1997, Power, Elias et al. 2000). 
The main known physiological role of TTR is the transport of thyroid hormone 
thyroxine (T4) (Palha 2002) as well as of retinol (vitamin A) that is bound to retinol binding 
protein (RBP) (Butler, Chan et al. 2016). TTR in blood transports about 15% of plasma T4 
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whereas TTR in CSF transports approximately 80% of the available T4. This difference is 
mostly due to the presence of other T4 transporters in blood, such as thyroxine binding 
protein and albumin (Chen, Chen et al. 2016). Despite its role in transport, TTR knockout 
mice did not show impaired T4 or retinol metabolism (Palha, Hays et al. 1997, Sousa, de 
Escobar et al. 2005).  
TTR was also described as a protease, capable of cleaving apolipoprotein A1 
(ApoA1) in vitro, and lipidated ApoA1, a relevant action since this cleavage decreases its 
ability to promote the efflux of cholesterol (Liz, Faro et al. 2004, Liz, Gomes et al. 2007). 
Furthermore, another proteolytic action by TTR was found: TTR is capable to cleave Aβ 
peptide, suggesting that TTR could be involved in Aβ clearance. Moreover, the originated 
Aβ species present reduced amyloidogenic potential, as compared to the full-length peptide 
(Costa, Ferreira-da-Silva et al. 2008). Liz et al. also showed that TTR is able to cleave 
amidated neuropeptide Y. All together these data suggests that TTR has natural substrates in 
the nervous system (Fleming, Mar et al. 2009, Liz, Fleming et al. 2009).  
TTR was also shown to be neuroprotective in the central nervous system, namely in 
ischemia (Santos, Lambertsen et al. 2010), regeneration (Fleming, Mar et al. 2009) and 
memory (Sousa, Marques et al. 2007). 
 
 
3.2. TTR as a cause of disease 
TTR is the key protein in Familial Amyloid Polyneuropathy (FAP), a 
neurodegenerative disease caused by the accumulation of mutant TTR in several organs and 
tissues, with a special involvement of the peripheral nervous system (Hammarstrom, 
Wiseman et al. 2003). Other pathologies associated to TTR aggregation are senile systemic 
amyloidosis and familial amyloid cardiomyopathy (Buxbaum and Reixach 2009).  
FAP was firstly described by Dr. Corino de Andrade (Andrade 1952), and is a 
hereditary autosomal dominant disease. A large number of mutations are already described, 
being the substitution of a valine residue for a methionine at position 30 (V30M TTR) the 
most common (Saraiva, Birken et al. 1984, Fleming, Mar et al. 2009). Other mutations have 
been studied and associated with very different clinical phenotypes/roles. For example, L55P 
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TTR is associated with one of the most aggressive forms of TTR-related amyloidosis 
(Jacobson, McFarlin et al. 1992). However, T119M TTR is characterized as a non-aggressive 
mutation that has a protective role against the disease (Almeida, Alves et al. 2000). It is 
suggested that the amyloidogenic potential of TTR variants depend on its tetrameric stability 
and it is the dissociation of the tetramer into monomers the basis of a series of events that 
will lead to TTR amyloid formation (Cardoso, Goldsbury et al. 2002).  
 
3.3. TTR as a neuroprotective protein in AD 
 
 Since Schwarzman and colleagues, the first group to find a relation between TTR and 
Aβ, suggested that TTR could have a neuroprotective role in AD, several studies have been 
done to understand the relationship between TTR and Aβ. In their study, Schwarzman and 
colleagues  showed that TTR is the major Aβ sequestering protein in CSF, preventing 
amyloid formation (Schwarzman and Goldgaber 1996). Moreover, this was highlighted by 
the observation that AD patients present decreased TTR levels in the CSF (Hansson, 
Andreasson et al. 2009) and in plasma/serum (Ribeiro, Santana et al. 2012). Importantly, 
TTR levels correlate with disease state, meaning that TTR could be a biomarker (Ribeiro, 
Santana et al. 2012, Velayudhan, Killick et al. 2012).  
 In vivo data obtained from AD transgenic mice established in different TTR genetic 
backgrounds demonstrated that the genetic reduction of TTR resulted in increased Aβ 
amyloid burden and total Aβ brain levels (Oliveira et al, 2011). 
Furthermore, Costa and colleagues revealed that TTR is capable of binding to 
different Aβ species: soluble, oligomers and fibrils (Costa, Goncalves et al. 2008), and even 
of inhibiting and disrupting Aβ fibrils, suggesting this inhibition/disruption as a protective 
role of TTR in AD. Moreover, in a study performed using different TTR variants, it was 
shown that T119M presented the highest affinity to Aβ and L55P the lowest, suggesting that 
amyloidogenic potential of TTR is correlated inversely with binding affinity to Aβ (Costa, 
Goncalves et al. 2008). In the same work, however, authors showed that TTR L55P has the 
ability to inhibit Aβ fibril formation and even disrupt fibrils in a similar level as WT TTR, as 
shown by electron microscopy (Costa, Goncalves et al. 2008). However, the following 
experiments, using more sensitive assays, showed that L55P does not inhibit Aβ oligomer 
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formation nor protects against Aβ toxicity (Ribeiro, Saraiva et al. 2012). Very recently, it 
was suggested that TTR proteolytic activity is required for the neuroprotective effect of the 
protein (Silva, Eira et al. 2017). 
Also recently, Alemi and colleagues showed that TTR participates in Aβ brain efflux 
at the BBB (Alemi, Gaiteiro et al. 2016). Using the hCMEC/D3 cell line as an in vitro model 
of the BBB, these authors showed that TTR, added to the brain side of the transwell system, 
was capable of increasing Aβ transport from the brain to the blood side. However, TTR added 
to the blood side had no effect the brain-to-blood permeability of hCMEC/D3 to Aβ peptide, 
indicating that TTR interacts directly with the peptide, probably transporting Aβ to its efflux 
receptor at the membrane. Interestingly, authors showed that TTR can cross in the brain-to-
blood direction but not in the blood-to-brain way, showing that TTR can participate in Aβ 
removal from the brain but cannot be responsible for its entry back into the brain, re-
enforcing a neuroprotective role for TTR in AD. 
 
3.3.1. Importance of TTR stabilization 
The idea involving the importance of TTR stabilization appeared in 1993, when 
McCutchen and colleagues showed the ability of L55P TTR to denaturate to the 
amyloidogenic intermediate at pHs where WT TTR remained stable, indicating a difference 
in the stability between both variants (McCutchen, Colon et al. 1993). 
To explore the state of TTR in AD, the binding between TTR and T4 was assessed 
using plasma from AD patients, showing a decreased ability of TTR to carry the hormone, 
indicating that this function was compromised (Ribeiro, Santana et al. 2012). This could 
suggest that TTR is unstable in AD, leading to its faster clearance, explaining its lower levels. 
These authors hypothesized that TTR stability is a key factor in the TTR-Aβ interaction and, 
consequently, that TTR tetrameric stabilization by small chemical compounds such as 
iododiflunisal (IDIF) and resveratrol would improve TTR binding to Aβ and AD features. 
In fact, IDIF administered orally to an AD mouse model resulted in decreased brain 
Aβ deposition, decreased Aβ levels in plasma, and also in improvement in cognitive 
functions associated to AD (Ribeiro, Oliveira et al. 2014). Moreover, in another study, 
resveratrol was administered in the diet of AD mice during two months, resulting in an 
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increase of TTR plasma levels and a decrease of brain Aβ plaque burden (Santos, Rodrigues 
et al. 2016). Very recently, Alemi and colleagues showed that TTR stability is critical in 
assisting Aβ clearance (Alemi, Silva et al. 2017). Overall, these results demonstrate that 
stabilization of TTR could be a promisor therapeutic strategy in AD.  
 
3.4. TTR as a CNS gene modulator  
The BBB is an important barrier in physiology and pathology, and because of that, 
several groups have been studying the influence of molecules in BBB features, being TTR 
one of them.  
Recently, studies have been done to unravel if TTR is a modulator of BBB, analyzing 
possible alterations in angiogenesis and gene expression. In fact, besides the direct action of 
TTR in Aβ, TTR can alter positively some important features of BBB.  
Initially, TTR was described as a molecule involved in regulation of Insulin-like 
growth factor receptor I (IGF-IR), having the capacity to increase IGF-IR levels in the 
hippocampus, both at transcript and protein level, demonstrated by studies in WT vs TTR-/- 
mice and in vitro-cultured cells (Vieira, Gomes et al. 2015). Later, the same group showed a 
synergy action of TTR and IGF-I in one of the IGF-IR signaling pathways, the Akt pathway. 
Here, TTR alone could not activate Akt pathway, but when it was simultaneously added with 
IGF-I, originated a stronger response compared with IGF-I alone (Vieira, Leal et al. 2016). 
Work by Alemi and colleagues showed that the ability of TTR to enhance Aβ brain 
efflux can result not only from a direct TTR/Aβ interaction and transport across the BBB, 
but also from capacity of TTR to modulate positively LRP1 levels (Alemi, Gaiteiro et al. 
2016), authors showed that both LRP1 transcript and protein levels were increased in TTR+/+ 
mice brains compared to TTR-/-; this result was confirmed in hCMEC/D3 cells that showed 
increased LRP1 levels in the presence of recombinant human with TTR. Altogether, authors 
propose that TTR is capable of mediating Aβ clearance through LRP1 (both at the brain and 
liver) (figure 14) (Alemi, Gaiteiro et al. 2016).  
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Relatively to angiogenesis, it was demonstrated the capacity of TTR to regulate 
angiogenesis, by comparing the expression of several pro-angiogenic genes, such as VEGF1 
and VEGFR2, in human umbilical vein endothelial cells (HUVECs), using WT TTR and 
V30M TTR. V30M TTR was capable to modulate negatively the expression of these genes 
compared to WT TTR. Moreover, V30M TTR inhibited endothelial cell migration using a 
wound healing assay (Nunes, de Oliveira et al. 2013). In a similar study, Shao and colleagues, 
trying to understand the effects of TTR in diabetic retinopathy (DR), compared the levels of 
pro-angiogenic genes in human retinal microvascular endothelial cells (hRECs) cultured with 
TTR in natural and simulated DR environments (hyperglycemia and hypoxia). Here, they 
observed that TTR led to the repression of cells proliferation and the development of 
neovascularization in a DR environment (Shao and Yao 2016).  
 
In summary, several studies highlight the importance of TTR as an important 
neuroprotective protein in AD through the sequestering and cleavage of Aβ peptide, and by 
assisting its elimination across the BBB, promoting its clearance. Moreover, TTR is also 
suggested to modulate positively the BBB, and thus it is possible that this protein impacts at 
the vascular system in other ways. 
Nevertheless, the ability of TTR to regulate angiogenesis in the brain has never been 
assessed, either in biological or in pathological conditions. Also, the interplay between TTR 
and other players in angiogenesis has not been studied. Finally, and although the genetic 
Figure 15. Representation of TTR-mediation in Aβ clearance (Cardoso I et al 2016) 
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reduction of TTR in AD mouse models results in increased Aβ brain deposition, AD features 
associated to vessel disease have not been evaluated in these models. Thus, this project aims 
at unravelling the possible relation between TTR and the brain vascular system 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Objectives 
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In this project, we aimed at investigating the impact of TTR in the brain vasculature. 
Previous reports implicated TTR in the regulation of the expression of pro-angiogenic genes 
in the eye and in the umbilical cord and thus, we aimed at further investigating the 
participation of TTR in brain vasculature, in biologic as in pathologic environments. 
In order to do that, our experiments had the following goals: 
 
1. To investigate the influence of TTR in the blood-brain barrier: 
a. Ascertain the effect of TTR in the gene expression of TJs-related genes at 
the transcript level using a global approach, the PCR array, and the 
traditional approach qRT-PCR, using hCMEC/D3 cells; 
 
b. Evaluate in hCMEC/D3 cells, the influence of TTR in the gene expression 
of TJs-related genes at the protein level by immunocytochemistry; 
 
c. Explore the modulator role of TTR on the angiogenesis capacity of two 
different types of immortalized endothelial cells, hCMEC/D3 and bEnd.3 
cells, by qRT-PCR and in vitro wound healing assay. 
 
2. To assess whether TTR impacts on brain vasculature, specifically in the basal 
membrane, in AD and non-transgenic mice: 
a. Evaluate and compare the levels of collagen IV in brain vessels of 
AD/TTR+/+, AD/TTR+/- and AD/TTR-/- female mice, at seven months, by 
immunohistofluorescence; 
b. Identify how TTR is implicated in collagen IV changes in brain vessels 
using a non-transgenic model; 
c. Confirm the involvement of TTR in the alteration of collagen IV levels in 
AD/TTR+/- mice treated or non-treated with IDIF; 
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d. Explore the role of Aβ in the thickening of the BM, namely in the collagen 
IV layer, in cell culture, using the bEnd.3 cell line. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Material and Methods 
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1. Recombinant TTR production and purification 
Human recombinant TTR variants were produced in a bacterial expression system 
using Escherichia coli BL21 (Furuya, Saraiva et al. 1991) and purified in a similar way as 
described before (Almeida, Damas et al. 1997).  
Firstly, E. coli BL21 were transformed with pET plasmids carrying TTR variants 
cDNA (WT TTR, V30M TTR or L55P TTR). Transformed bacteria were grown overnight 
(O/N) in 15-ml starter cultures of Lubia-Bertani (LB) medium containing 50 µg.mL-1 of 
ampicillin at 37ºC and 180 rpm. One-liter cultures with LB containing ampicillin were 
inoculated with starter culture and incubated at 37ºC and 180 rpm until reach an optical 
density of 0.4-0.5. Then, TTR expression was induced with 500 µM of Isopropyl β-D-1-
thiogalactopyranoside (IPTG), and the culture was grown for 6 h at 37ºC and 180 rpm. Next, 
culture media was centrifuged at 4000 rpm for 10 min at 4ºC and the supernatant was 
discarded. The pellet was resuspended in lysis buffer (1M Tris pH 7.5, 0.5 M 
Ethylenediamine tetraacetic acid (EDTA), Triton-X, Phenylmethylsulfonyl fluoride (PMSF) 
and 10 µg.mL-1 DNAse), and bacterial cell disruption was performed by successively freeze-
thaw-freeze the solution and by sonication. In order to remove cell debris and obtain only the 
soluble proteins, it was performed a centrifugation at 15000 rpm for 25 min at 4ºC. Pellet 
was discarded and the supernatant was dialyzed O/N in glycine-acetate at 4ºC. 
For TTR purification, firstly, we performed an ion-exchange chromatography. The 
dialyzed solution was passed through an ion exchange column of diethylaminoethyl (DEAE)-
cellulose (Sigma). The column was washed with glycine-acetate buffer, pH=7.0, and the 
fraction containing TTR was eluted by increasing the ionic strength, using an solution of 
glycine-acetate +3% sodium chloride. Then, this fraction containing TTR protein was 
dialyzed against water and lyophilized. TTR was finally isolated by preparative 
electrophoresis in a native Prosieve agarose (Lonza) gel. The slice of the gel containing TTR 
was cut and eluted in 38 mM glycine and 5 mM Tris. TTR variants purity was analyzed by 
Coomassie blue staining and protein identification by Western Blot and by Peptide Mass 
Fingerprint (PMF+MALDI-TOF). Protein concentration was determined using the Bradford 
Method, using bovine serum albumin (BSA) as standard. 
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2. Preparation of Aβ species 
Synthetic Aβ42 (Genscript) was dissolved in hexafluoro-2-propanol (HFIP) (Sigma) 
and kept at room temperature (RT) overweekend. After, the HFIP was removed under a 
stream of nitrogen and the powder was dissolved in DMSO at 2 mM. From this stock, three 
different species of Aβ42 were produced: soluble, oligomers and fibrils. Aβ42 was diluted to 
100 µM in Ham’s F12 medium and then incubated at 4ºC during three days for oligomer 
formation or at 37ºC for seven days for fibril formation. Soluble Aβ42 was obtained by 
diluting the peptide to 100 µM in Ham’s F12 medium immediately before adding to cells. To 
confirm the presence of the different Aβ42 species, samples were visualized by transmission 
electron microscopy. 
 
3. Transmission electron microscopy 
For visualization by transmission electron microscopy (TEM), samples aliquots of 
Aβ42 species were absorbed to carbon-coated collodion film supported on 300-mesh zinc 
grids, and negatively stained with 1% uranyl acetate. The grids were visualized with a JOEL 
JEM-1400 transmission electron microscope equipped with an Orious Sc1000 digital camera. 
 
 
4. Cell culture 
Two different cell lines were used as a model of BBB in this work: the immortalized 
human cerebral microvascular endothelial cell line (hCMEC/D3 cell line) , purchased at 
Tebu-Bio, and the immortalized mouse brain endothelial cell line bEnd.3, which was kindly 
provided by Dr. Teresa Summavielle (I3S, Porto). To originate these cell lines, endothelial 
cells were isolated from the temporal lobe of brain of an adult female human with epilepsy 
and from an endothelioma in the cerebral cortex from mouse brain, respectively. Both cell 
types were cultured following the available cell line data sheet. 
hCMEC/D3 cells were used between passages 25 and 35. Cells were seeded in cell 
culture flasks or plates coated with rat tail collagen type I (coating of the surfaces was 
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performed using a solution of rat tail collagen type I (Sigma) at a concentration of 150 µg.mL-
1 during 1-2 hours at 37ºC. hCMEC/D3 cells were grown in EBM-2 medium (Lonza) 
supplemented with 5% Fetal Bovine Serum (FBS) (Gibco), 1% Penicillin-Streptomycin 
(Lonza), 1.4 µM of Hydrocortisone (Sigma), 5 µg.mL-1 of Acid Ascorbic (Sigma), 1% of 
Chemically Defined Lipid Concentrate (Gibco), 10 mM of 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) (Gibco) and 1 ng.mL-1 of bFGF (Sigma).  
bEnd.3 cells were used between passages 25 and 30. Cells were grown in Dulbecco’s 
Modified Eagle Medium (DMEM) (1x) + GlutaMAX (Gibco) supplemented with 10% FBS 
(Gibco) and 1% Penicillin-Streptomycin (Lonza). 
 
5. Gene expression – qRT-PCR 
For Real-Time Polymerase Chain Reaction (qRT-PCR) analysis, both cell lines were 
used. Firstly, cells were incubated in the absence or presence of TTR variants for 24h (for 
analysis of TJs-related genes) or 8h (for analysis of angiogenesis-related genes), and total 
RNA was then isolated from cells using Trizol reagent (Invitrogen) following the instructions 
available in the product datasheet. RNA concentration and purity was quantified by reading 
the absorbance at 260 nm and the A260/A280 ratio, respectively, with NanoDrop photometer 
(Thermo Fisher Scientific), and RNA integrity was determined by running RNA samples on 
a 1% agarose gel stained with GreenSafe Premium (NZYtech). Then, 2 µg of RNA were 
first-reversed transcribed into cDNA using NZY First-Strand cDNA Synthesis kit (ZNYtech) 
and cDNA was saved at -20 ºC until used. Next, gene expression of tight junction-related 
genes and angiogenesis-related genes was evaluated by qRT-PCR. To evaluate a large set of 
genes related with tight junction proteins, a qRT-PCR was performed using a pre-designed 
PrimePCR Pathway Plate (Tight Junctions H96, BioRad), according to the manufacturer’s 
protocol. Alternatively, primers were designed for some of the tight junction-related genes, 
according to their sequence available in the National Center for Biotechnology Information 
(NCBI) and using the functionality Primer-BLAST available in the same website. For the 
angiogenesis-related genes, human sequences available in the literature were used and the 
corresponding primers for mouse samples were designed as described above. Table 1 
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describes all primers designed in-house, whereas primers from the pre-designed PrimePCR 
Pathway Plate are not disclosed by the manufacturer. 
Human or mouse GAPDH were used as an internal control for normalization. The 
reaction mix was done with the SYBR green reporter (iQ SYBR green supermix, BioRad) 
following the instructions presented by the manufacturer. PCR primers and conditions used 
for all analyzed genes are shown in table 1. The qRT-PCR was performed using the CFX96 
Touch Real-Time PCR Detection System (BioRad). The relative quantification was 
performed according to the comparative method (2-ΔΔct) (Livak and Schmittgen 2001). 
 
Table 1. Sequences of the “in-house designed” primers. PCR condition was the same for all primers. 
 
 
 
 
 
Cell 
line Gene Primer Sequence PCR condition 
hC
M
EC
/D
3 
CLDN1 
Forward: 5’ CCCAGTCAATGCCAGGTACG 3’ 
Reverse: 5’ CAAAGTAGGGCACCTCCCAG 3’ 
Initial denaturation: 
95ºC, 3 minutes 
 
Denaturating, 
annealing and 
extension (40 cycles): 
 
95ºC, 15 seconds 
 
60ºC, 30 seconds 
JAM-2 
Forward: 5’ CGCCCTGGGCTATCATAAGG 3’ 
Reverse: 5’ CAAAGGAGACACTCCGACCC 3’ 
CLDN3 
Forward: 5’GACCAACCTGCATGGACTGT 3’ 
Reverse: 5’ TCAAGTATTGGCGGTCACCC 3’ 
CTNNB1 
Forward: 5’ GTCTGAGGAGCAGCTTCAGT 3’ 
Reverse: 5’ ACTTCAAATACCCTCAGGGGAAC 3’ 
CDH5 
Forward: 5’ CTTCACCCAGACCAAGTACACA 3’ 
Reverse: 5’ AATGGTGAAAGCGTCCTGGT 3’ 
VEGFR1 
Forward: 5’ CCCTCGCCGGAAGTTGTAT 3’ 
Reverse: 5’ GTCAAATAGCGAGCAGATTTCTCA 3’ 
VEGFR2 
Forward: 5’ ATTCCTCCCCCGCATCA 3’ 
Reverse: 5’ GCTCGTTGGCGCACTCTT 3’ 
ANGPT2 
Forward: 5’ AGGACACACCACGAATGGCATCTA 3’ 
Reverse: 5’ TGAATAATTGTCCACCCGCCTCCT 3’ 
bE
nd
.3
 VEGFR1 
Forward: 5’   GTGTCTATAGGTGCCGAGCC 3’ 
Reverse: 5’  CGGAAGAAGACCGCTTCAGT 3’ 
VEGFR2 
Forward: 5’  GCATACCGCCTCTGTGACTT 3’ 
Reverse: 5’  AAATCGCCAGGCAAACCCAC 3’ 
TGFB2 
Forward: 5’  AAAATCGACATGCCGTCCCA 3’ 
Reverse: 5’  ATGGCATCAAGGTACCCACA 3’ 
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6. Immunocytochemistry 
hCMEC/D3 and bEnd.3 cells were grown on glass coverslips (Thermo Fisher 
Scientific) previously autoclaved. Cells were grown until reach 70% confluence and then 
incubated with their respective media in the absence or presence of TTR variants. 
To study TJs protein levels, hCMEC/D3 cells were incubated with WT TTR (2 µM) 
or V30M TTR (4 µM) for 24h. For the study of collagen type IV levels, bEnd.3 cells were 
treated with WT TTR alone (2 µM) or with Aβ alone (10 µM) or with TTR and Aβ together, 
for 24h. Then, cells were washed with PBS and fixed with methanol for 15 min at RT. 
Following fixation, cells were permeabilized with 0.25% Triton X-100 in PBS for 10 min at 
RT. Next, blocking was performed with 5% BSA in PBS for 1h, followed by an overnight 
incubation with primary antibodies at 4ºC against the proteins of interest (table 2). After 
being washed with PBS, cells were incubated with the Alexa Fluor-488 donkey anti-rabbit 
IgG antibody (Invitrogen 1:1000) for 1h at RT. Coverslips were mounted with 
FluoroshieldTM with DAPI (Sigma-Aldrich). Visualization was done with the Zeiss Axio 
Imager Z1 microscope equipped with an Axiocam MR3.0 camera and Axivision 4.9.1 
software. 
 
Table 2. List of primary antibodies used in immunocytochemistry analysis. 
Cell line Protein Primary antibody Dilution 
hCMEC/D3 Occludin 
Polyclonal rabbit 
antibody anti-human 
occludin (Invitrogen) 
1:12.5 
hCMEC/D3 Claudin-3 
Polyclonal rabbit 
antibody anti-human 
claudin-3 (Invitrogen) 
1:12.5 
bEnd.3 Collagen IV 
Polyclonal rabbit 
antibody anti-mouse 
collagen IV (Abcam) 
1:200 
 
7. Wound Healing Assay 
A wound healing assay was performed using both cell lines in a similar way. Cells 
were allowed to grow until confluence in a 12-well plate, and wounds were created in the 
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cell monolayer by scraping the plate with a 200 µl pipette tip. A single wash was performed 
to remove detached cells and media was then added in the presence or absence of TTR 
variants. Wounded monolayers were photographed immediately after wounding (t = 0h) and 
6h, 8h and 10h later. The results were normalized for wound area at t= 0h and expressed as 
percentage of wound healing. 
 
8. Animals 
To evaluate collagen IV deposition in brain vessels, two mice models were used, an 
AD transgenic model and a non-transgenic model, both established in different TTR genetic 
backgrounds. The AD mouse model AβPPswe/PS1A246E/TTR transgenic mice was 
generated by crossing the AD mouse model AβPPswe/PS1A246E (Borchelt, Ratovitski et al. 
1997) (B6/C3H background) purchased from The Jackson laboratory with TTR-null mice 
(TTR-/-) (SV129 background) (Episkopou, Maeda et al. 1993) as previously described 
(Oliveira, Ribeiro et al. 2011). As we intended to study the role of TTR in certain AD 
features, we used cohorts of littermates with different genetic backgrounds: 
AβPPswe/PS1A246E/TTR+/+ (carrying 2 copies of the TTR gene), 
AβPPswe/PS1A246E/TTR+/− (carrying 1 copy of the TTR gene) and 
AβPPswe/PS1A246E/TTR−/− (without TTR). In the next sections, the different genotypes 
AβPPswe/PS1A246E/TTR+/+, AβPPswe/PS1A246E/TTR+/-, AβPPswe/PS1A246E/TTR-
/−, will be mentioned to as AD/TTR+/+, AD/TTR+/- and AD/TTR-/-, respectively. Tissues 
from these mice were already available in the lab from previous studies, and thus, these 
animals were not handled in the context of the current project. Brain tissue from AD/TTR+/- 
7 months-old female mice treated with the TTR stabilizer iododiflunisal, also available in the 
lab from previous work (Ribeiro et al, 2014), were also analyzed in this work. 
As stated, a non-transgenic mouse model containing different TTR backgrounds – 
TTR-wild type (+/+) and TTR-heterozygous (+/-) - was also studied. All mice were obtained 
from the same littermate as AD mice and were female aged 7 months.  The different 
genotypes will be mentioned as TTR+/+ (TTR-wild type) and TTR+/- (TTR-heterozygous). 
Animals were housed in a controlled environment (12-h light/dark cycles, 
temperature between 22-24 °C, humidity between 45–65% and 15-20 air changes/hour), with 
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freely available food and water. All the above experiments were approved by the Institute for 
Research and Innovation in Health Sciences (i3s) Animal Ethics Committee and in agreement 
with the animal ethics regulation from Directive 2010/63/EU. 
 
9. Tissue processing 
TTR mice were anaesthetized with an intraperitoneal injection of a mixture of 
medetomidine (1 mg/kg) and ketamine (75 mg/kg). After anesthesia, the thorax was opened 
and it was exposed the heart. Then, it was placed a perfusion needle through the left ventricle 
into the ascending aorta and before start the perfusion, an incision in the right atrium was 
made. Firstly, PBS was perfused at a rate of 2 mL/min for 4 min, followed by perfusion of 
4% paraformaldehyde (PFA) at a rate of 2 mL/min for 4 min. Following the perfusion, brains 
were removed and bisected longitudinally: each half of the brain was either frozen at -80 ºC 
for potential biochemical analysis and brain microvessel isolation, or fixed for 24h at 4ºC in 
4% PFA. After, this last half brain was washed with PBS and then transferred to a 30% 
sucrose solution for cryoprotection before cryostat sectioning and immunohistochemical 
analyses.  
 
10. Immunohistochemistry 
To investigate collagen IV levels in brain vessels, 30 µm-thick coronal brain sections 
of mice were washed with PBS and dried O/N at RT on APES-precoated slides. Then, 
sections were permeabilized with 0.25% Triton X-100 in PBS for 10 min at RT, blocked with 
5% BSA in PBS for 1h at RT and incubated with anti-collagen IV primary antibody (1:100) 
(Abcam) in 1% BSA in PBS overnight at 4ºC. Next, sections were washed with PBS and 
incubated with Alexa Fluor-568 donkey anti-rabbit IgG antibody for 1h at RT. To remove 
tissue autofluorescence, sudan black B solution (0.3% sudan black B in 70% ethanol) was 
applied for 5 min at RT, followed by washing one time with water and after with PBS. Then, 
brain sections were mounted with FluoroshieldTM with DAPI (Sigma-Aldrich) and 
visualization was done with the Zeiss Axio Imager Z1 microscope equipped with an Axiocam 
MR3.0 camera and Axivision 4.9.1 software. A total of fifteen randomly selected vessels in 
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the cortex of each mouse were photographed and the intensity of signal was measured using 
the ImageJ software. 
 
11. Isolation and characterization of mouse brain microvessels 
Isolation: Brain microvessels were isolated essentially as described previously (Qosa, 
Abuznait et al. 2012). Frozen brains from three mice were used. Briefly, brains were 
homogenized in Dulbecco’s Phosphate-Buffered Saline (DPBS) with a Potter Tissue Grinder 
with 20 up-and-down strokes. To the homogenate, one volume of Ficoll 400 (30%) (Sigma) 
was added to a final concentration of 15%, and then centrifuged at 5000 rpm for 10 min at 
4ºC. The resulting pellet was suspended in ice-cold DPBS containing 1% BSA and passed 
over a bead column. The bead column was made by cutting both ends of a 3-mL syringe, and 
one end was closed with a 70 micron cell strainer. Then, acid-wash glass beads (425-600 µm) 
(Sigma) were poured into the column extending to 1.5 cm from the filter. At this point, 
microvessels are attached to the beads and cell debris will be present in the flowthrough. The 
column was washed several times with DPBS and glass beads were transferred to a sterile 
100 mm culture dish containing DPBS, followed by gently shaking the dish to separate 
microvessels from the beads. Finally, the microvessel suspension was centrifuged at 1000 g 
for 12 min at RT and the pellet resuspended in a small volume of DPBS. 
Characterization: Firstly, some drops of hematoxylin were added to a small volume 
of microvessels suspension, and then placed in a microscope slide for further visualization. 
Microvessels were transferred to glass slide and let O/N at 37ºC to allow adhesion. Then, 
microvessels were washed with PBS, fixed for 15 min with 4% PFA at RT and permeabilized 
with 0,1% (v/v) Triton X-100 in PBS for 15 min. Blocking was performed with 1% BSA in 
PBS for 1 h, followed by incubation with primary antibodies at 4ºC against LRP1 (Abcam) 
and CD31 (Abcam) (both 1:100). After being washed with PBS, cells were incubated with 
the Alexa Fluor-488 donkey anti-rabbit and Alexa Fluor-568 donkey anti-mouse IgG 
antibody (Invitrogen 1:1000) for 1h at RT. Nuclei were stained with FluoroshieldTM with 
DAPI (Sigma-Aldrich). Visualization was done with the Zeiss Axio Imager Z1 microscope 
equipped with an Axiocam MR3.0 camera and Axivision 4.9.1 software. 
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12. Statistical Analysis 
All quantitative data were expressed as mean value ± standard deviation (SD), in case 
of n ≥ 5, data were expressed as mean ± standard error of the mean (SEM). qRT-PCR and 
wound healing assay results were statistically analyzed for significant difference using two-
tailed Student’s t-test. Differences in brain collagen IV levels were analyzed using one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test when three 
different mice genotypes were compared or Student’s t-test when only two different mice 
genotypes were compared. p-values lower than 0.05 were considered statistically significant. 
Statistical analyses were performed using GraphPad Prism 6 software for Windows. 
 
  
 
 
 
 
 
 
Results 
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1. Effect of TTR on tight junction-related genes 
1.1. At the transcript level 
As referenced in the introduction, TTR is capable to modulate important genes of 
BBB such as LRP1, but there are no published studies on the effect of TTR on TJs, which 
are extremely important components of the BBB. As a first approach, we evaluated the 
transcription level of several tight junction-related genes in hCMEC/D3 cells using a PCR 
array, since it allows to analyze changes in gene expression of numerous genes at the same 
time. 
With this objective, changes in the transcript level were investigated by comparing 
hCMEC/D3 cells incubated in the absence or presence of WT TTR, at the final concentration 
of 2 µM for 24h. We choose this condition because it was previously used by authors to study 
the modulation role of TTR in gene expression (Alemi, Gaiteiro et al. 2016). Alterations in 
gene expression are presented as the ratio between WT-treated cells and control (absence of 
TTR). 
As shown in figure 15, qRT-PCR results indicate that TTR induced alterations in gene 
expression of several genes. The most pertinent alterations obtained were the up-regulation 
of JAM-2 and CLDN1, and down-regulation of CLDN2 and TJP3. Curiously, these results 
Figure 16. PCR array analysis of gene expression of several TJs-related genes. A PCR array was used to characterize 
endothelial cells response to WT TTR. hCMEC/D3 were incubated with or without WT TTR at the final concentration of 
2µM for a period of 24h. Data represent the normalized gene expression of each target in TTR-treated cells relative to the 
control. A “pool” of cDNA constituted by 3 different cDNAs was used. 
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suggest that TTR alters the gene expression of different genes of the same family in a 
different way, such as the CLDN family. It is also possible to observe that numerous genes 
present the same transcript level with or without TTR. 
Although arrays are a good tool to study global transcriptional alterations, we do not 
have knowledge of the sequences of the primers used. Thus, we decided to confirm the results 
for the two most up-regulated genes, JAM-2 and CLDN1, by using primers designed by us. 
 Surprisingly, the results obtained using the commercial PCR array were not validated 
for both genes, since no differences in gene expression of CLDN1 and JAM-2 were verified 
(figure 16A).  
 
Moreover, we analyzed the gene expression of three other genes, CLDN3, CTNNB1 
and CDH5, which are also important in tight junction formation, and were not evaluated in 
the commercial PCR array. As observed in figure 16B, analysis by qRT-PCR showed no 
significant differences for all these three genes. 
 
1.2. Effect at the protein level 
It is commonly known that there is a low correlation between mRNA level and its 
coding protein level, despite being reasonable to see high protein level with high mRNA level 
(or the opposite case). 
Figure 17. qRT-PCR analysis of TJs-related genes using “in-house” primers. hCMEC/D3 cells were incubated with or 
without TTR (2 µM) for 24h. (A) Transcript levels of CLDN1 and JAM-2 were not altered by the presence of TTR, not 
validating the results obtained using the PCR array. (B) CLDN3, CTNNB1 and CDH5 did not show differences in gene 
expression at the transcript level with TTR incubation. Data represent the –fold change in gene expression of each target in 
TTR-treated cells relative to the control. 
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In this sense, we decided to further confirm if TTR has no effect in tight junction-
related genes expression by performing immunofluorescence analysis, verifying protein 
levels of two important tight junction proteins, OCLN and CLDN3, which were analyzed in 
the PCR array and individual qRT-PCR, respectively. 
Similarly to the previous study of gene expression at transcript level, protein level 
was investigated by comparing hCMEC/D3 cells incubated in the absence or presence of WT 
TTR, at the final concentration of 2 µM for 24h. Moreover, we also incubated cells with 
V30M TTR at the final concentration of 4 µM for 24h to evaluate if this variant associated 
with disease could change CLDN3 protein level.  
Immunofluorescence results demonstrated that WT TTR did not change the protein 
level of both proteins (figure 17), corroborating the results obtained at the transcript level, 
where no significant differences were obtained for these proteins. Also, V30M TTR was not 
capable to affect gene expression at the protein level of CLDN3. 
 
Figure 18. Analysis of protein level of tight junctions in hCMEC/D3 cells without or with incubation of TTR for 
24h. Immunofluorescence analysis of Occludin and Claudin-3 expression in hCMEC/D3 cells stained with an antibody 
against each protein (green). Nucleus of cells are stained with DAPI (blue). 
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Altogether, these observations indicate that TTR has no effect in gene expression of 
tight junction-related genes in hCMEC/D3 cells, both at the transcript and protein levels, in 
the conditions and cell type used. 
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2. Effect of TTR on the angiogenic capacity of endothelial cells  
A previous study, using HUVEC, explored the biological effect of TTR variants on 
angiogenesis (Nunes, de Oliveira et al. 2013). In this work, authors compared the effect of 
WT TTR vs V30M TTR, concluding that the two TTR variants induced a different response 
with regard to the angiogenic capacity, since in the presence of V30M TTR, cells expressed 
less the pro-angiogenic genes as compared to cells incubated with WT TTR. In this work, 
however, researchers did not evaluate if TTR per se is important for regulation of 
angiogenesis, i.e. comparison between the presence of WT TTR and cell culture media alone 
was not performed. 
2.1 Effect of TTR variants in the expression of pro-angiogenic 
genes in hCMEC/D3 cells 
Following what was previous said, we designed our study aiming at evaluating the 
role of TTR in brain angiogenesis. In order to understand it, we examined the expression of 
genes known to be important in angiogenesis, such as VEGFR1, VEGFR2 and ANGPT2. 
For this, we incubated cells in the absence or presence of WT TTR (4 µM) and V30M TTR 
(4 µM) for 8h, replicating the conditions used by the authors of the previous study (mentioned 
above), but using the hCMEC/D3 cell line. 
Figure 19. qRT-PCR analysis of pro-angiogenic genes in hCMEC/D3 cells. Cells were incubated with 
or without TTR variants for 8h at a final concentration of 4 µM. Transcript levels of three different pro-
angiogenic genes are presented. Data represent the –fold change in gene expression of each target in TTR-
treated cells relative to the control. 
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According to our qRT-PCR results, the expression of such genes, at the transcript 
levels, did not change at 8 h (figure 18), and thus, similar levels were found in the absence 
or presence of TTR variants. These results indicate neither variant modulated the expression 
of these angiogenesis-related genes, neither positively nor negatively. Importantly, we also 
did not see a difference in the gene expression between WT TTR and V30M TTR. It is 
important to highlight it, since Nunes and colleagues verified a down-regulation of these 
three genes with V30M TTR, comparing to WT TTR.  
 
2.2 Effect of TTR variants in the hCMEC/D3 cells migration 
capacity. 
Moreover, and to confirm that TTR is not involved in angiogenic-related events, we 
also evaluated migration, an essential part of the angiogenesis process. For that, hCMEC/D3 
cells were cultured until confluent, followed by scraping the monolayer, initiating the wound 
process. Then, hCMEC/D3 cells were exposed to different TTR variants (WT, V30M and 
L55P) at the final concentration of 4 µM. As observed in figure 19, the ECs migratory 
response was similar between control and all TTR variants, since cells incubated in the 
absence or presence of TTRs achieved similar wound area at 8h, meaning that independently 
on the TTR variant, the presence of TTR does not alter the capacity of cells to migrate. 
Similarly, the presence of WT TTR at different concentrations did not influence hCMEC/D3 
cell migration (figure 20). 
 
2.3. Impact of TTR variants in the migration capacity of bEnd.3 
cells 
Altogether, our results do not agree with the ones from two previous studies (Nunes, 
de Oliveira et al. 2013, Shao and Yao 2016). It is important to note that some experimental 
conditions were not the same which can account for the observed differences. For example, 
different batches of TTR can influence the results. Other important experimental difference 
is the cell lines used by both authors (HUVECs and hRECs) compared to ours (hCMEC/D3). 
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In order to explore the influence of the cell line in results, we used another cell line, the 
bEnd.3 cell line.  
As shown in figure 21, ECs migrated in a similar velocity, independently on the 
absence or presence of TTR. However, importantly, bEnd.3 cells do not appear appropriated 
A’ 
Figure 20. Effect of TTR variants on the migration of hCMEC/D3 cells. (A) hCMEC/D3 cells were cultured until 
confluent, and the monolayer was scraped with a 200 µl pippete tip to initiate wounding, following addition of TTR variants. 
Monolayers were followed over time and the wound area was measured at t = 0h and t = 8h. (A’) Quantification of results 
for each treatment was recorded and the means ± S.D. were calculated after normalizing for wounded area at t = 0h and 
expressed as percentage of wound area. 
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for migration studies at short times, since its migration happens very slowly – in our results, 
cells closed less than 10% of the wound during 10h -, being difficult to observe a possible 
effect. Despite it, we advance to the analysis of three angiogenesis-related genes by qRT-
PCR. Once again, no significant differences were observed between cells incubated with or 
without WT TTR (figure 21B). 
A’ 
A 
Figure 21. Effect of WT TTR concentration on the migration of hCMEC/D3 cells. (A) hCMEC/D3 
cells were cultured until confluent, and the monolayer was scraped with a 200 µl pippete tip to initiate 
wounding, following addition of WT TTR at different final concentrations. Monolayers were followed over 
time and the wound area was measured at t = 0h and t = 8h. (A’) Quantification of results for each treatment 
was recorded and the means ± S.D. were calculated after normalizing for wounded area at t = 0h and 
expressed as percentage of wound area. 
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Given our results, using both cell lines, we suggest that TTR does not modulate pro-
angiogenic genes and does not alter migration in hCMEC/D3 and bEnd.3 cells. 
 
  
  
Figure 23 
A’ B 
Figure 22. Effect of WT TTR on the angiogenic capacity and on gene expression of pro-angiogenic genes in bEnd.3 
cells. (A) bEnd.3 cells were cultured until confluent, and the monolayer was scraped with a 200 µl pippete tip to initiate 
wounding, following addition of WT TTR at two different final concentrations. Monolayers were followed over time and 
the wound area was measured at t = 0h, t = 6h, t = 8h and t = 10h. (A’) Quantification of results for each treatment was 
recorded and the means ± S.D. were calculated after normalizing for wounded area at t = 0h and expressed as percentage of 
wound area. (B) Transcript levels of three different pro-angiogenic genes were analyzed. Data represent the –fold change in 
gene expression of each target in TTR-treated cells relative to the control. 
A 
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3. Effect of TTR in collagen IV levels in AD  
The BM is an important element of the neurovascular unit, and acts as a mechanical 
barrier. Moreover, it is also essential to maintain BBB integrity and regulate angiogenesis. 
Several studies have already demonstrated that collagen IV, an important protein of BM, is 
increased in brain vessels of AD, both in patients and mice, compared to non-AD, suggesting 
that Aβ can be involved in this increase: These greater levels create a thick barrier, which 
can lead to an impairment of Aβ clearance by blocking its removal.  
Since TTR levels are decreased in AD, we asked whether there is a relationship 
between the decrease in TTR and the increase in the collagen layer. 
Thus, our first approach consisted in evaluating collagen IV levels in brain vessels of 
AD/TTR female mice 7 months old with different TTR backgrounds: AD/TTR+/+, AD/TTR+/- 
and AD/TTR-/-. Collagen IV levels were determined using immunohistofluorescence. As 
shown in figure 22, collagen IV levels are significantly increased in microvessels from 
AD/TTR+/- and AD/TTR-/- mice, compared to AD/TTR+/+, where AD/TTR+/- mice presented 
the highest amount of collagen IV. Although these results suggested that TTR influenced the 
thickness of the basement membrane, in particular the collagen IV layer, we could not 
determine if the effect was direct or indirect. It is very well established that TTR binds Aβ 
avoiding its aggregation and toxicity and promoting its elimination from the brain. One 
hypothesis is that high levels of Aβ, as it happens in AD, either due to increased production, 
reduced elimination or both could be responsible for the increase in collagen IV. As such, it 
is possible that AD/TTR+/- and AD/TTR-/- mice show increased amount of collagen IV 
because less TTR is available to interact with Aβ. Thus, in order to unravel this question, we 
firstly compared collagen IV levels in non-transgenic mice with two different TTR 
backgrounds, TTR+/+ and TTR+/-, allowing to understand if TTR is directly involved. 
Immunohistofluorescence results (Figure 23) revealed that decreased levels of TTR 
did not originate modifications in collagen IV levels in brain vessels. This result led us to 
conclude that TTR does not directly influence collagen IV, and most likely the results 
obtained with AD/TTR+/- and AD/TTR-/- mice indeed relate to the fact that less TTR is 
available to sequester Aβ peptide and to avoid its aggregation in the brain. 
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AD TTR+/- AD TTR+/+ AD TTR-/- 
Collagen IV 
A 
A’ 
Figure 22. Effect of TTR genetic reduction in collagen IV levels in AD mice. (A) Representative images of 
different vessels derived from AD mice with different TTR genetic backgrounds. Collagen IV levels (red) were 
evaluated by immunohistofluorescence with an anti-collagen IV antibody in 7-month-old AD TTR+/+ (n=7), AD 
TTR+/- (n=7) and AD TTR-/- female mice (n=3). (A’) Quantification of collagen IV levels, showing its significantly 
increased levels in microvessels from AD TTR+/- and AD TTR-/- mice compared to AD TTR+/+ mice, where 
AD TTR+/- mice presented the highest amount of collagen IV. Values shown as means ± SEM. *p<0,05; 
***p<0,001. 
 
  FMUP/IBMC-I3S  81 
  Results  
 
 
 
 
Following our hypothesis, we first decided to investigate if different Aβ species 
(soluble, oligomers and fibrils), can lead to an increase of collagen IV levels. Thus, we 
evaluated collagen IV levels in bEnd.3 cells incubated with 10 µM of each Aβ specie for 24 
hours. The presence of different Aβ species was confirmed by transmission electron 
microscopy (Figure 24). As it possible to observe, soluble Aβ solution presents already some 
aggregates (figure 24A). Preparation of a solution containing 100% of soluble Aβ using 
synthetic Aβ42 is highly challenging and nearly impossible. However, oligomers preparation 
(figure 24B) presented a high amount of Aβ oligomers and aggregates with different sizes. 
The fibrils preparations (figure 24C), which are very distinct from the other species, 
Figure 23. Effect of TTR genetic reduction in collagen IV levels in brain vessels. (A) Representative images of different 
vessels derived from mice with different TTR genetic backgrounds. Collagen IV levels (red) were evaluated by 
immunohistofluorescence with an anti-collagen IV antibody in 7-month-old TTR+/+ (n=3) and TTR+/- (n=3) (A’) 
Quantification of collagen IV levels, showing no significant differences in microvessels from TTR+/+ and TTR+/-. Values 
shown as means ± S.D.  
A 
A’ 
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presented the characteristic fibrillary structure with different lengths, but still with some 
oligomers. 
 
Immunofluorescence results (figure 25) reveal that, in fact, Aβ leads to an increase of 
collagen IV levels, supporting our hypothesis. Moreover, the increase of collagen IV is 
independent on the Aβ specie, since no differences between species were observed. However, 
due to the difficulty in obtaining soluble, monomeric Aβ, care must be taken when drawing 
such conclusions. 
 
 
 
 
Figure 24. Morphological characterization of Aβ species by TEM analysis. Visualization of (A) Soluble Aβ, (B) 
Oligomers and (C) Fibrils using TEM. 
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To ascertain if TTR exerts a neuroprotective role in the decrease of collagen IV levels 
by decreasing Aβ effects through its clearance, we evaluated if the simultaneous presence of 
TTR and Aβ results in the preservation/normalization of collagen IV levels. Thus, we 
incubated bEnd.3 cells with TTR alone, soluble Aβ alone or both together for 24 h. 
Figure 25. Analysis of collagen IV levels in bEnd.3 cells without or with incubation of Aβ species for 24h. 
Immunofluorescence analysis of Collagen IV expression in bEnd.3 cells stained with an antibody against our target 
(green). Nucleus of cells are stained with DAPI (blue). 
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Visualization of immunofluorescence results (figure 26) shows that Aβ leads to an 
increase of collagen IV levels (as also shown in figure 25), while TTR didn’t alter the amount 
of this BM’s protein. Interestingly, when Aβ and TTR were incubated simultaneously, no 
differences in collagen IV amount were observed.  
 
Work developed in our lab has previously indicated that TTR stability is impaired in 
AD; stabilizing TTR with small chemical compounds known to stabilize its tetrameric fold 
was then suggested as a therapeutic avenue in AD. Administration of IDIF to AD mice, a 
potent TTR stabilizer, resulted in amelioration of some AD features, such as the cognitive 
function and decreased Aβ brain levels. In this work, we evaluated the collagen IV layer in 
AD/TTR+/- animals, non-treated versus IDIF-treated. As depicted in figure 27, AD/TTR+/- 
mice treated with IDIF presented a significant decrease in collagen IV levels, presenting new 
evidence for the involvement of TTR.  
Figure 26. Analysis of collagen IV levels in bEnd.3 cells with incubation of TTR alone, 
Aβ alone or both together. Immunofluorescence analysis of Collagen IV expression in 
bEnd.3 cells stained with an antibody against our target (green). Nucleus of cells are stained 
with DAPI (blue). 
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Figure 27. Effect of IDIF treatment in collagen IV levels of AD/TTR+/- mice brain.
(A) Representative images of different vessels derived from AD/TTR+/- mice treated
without or with IDIF. Collagen IV levels (red) were evaluated by 
immunohistofluorescence with an anti-collagen IV antibody in 7-month-old AD/TTR+/-
non-treated (n=7) or treated (n=7) with IDIF (A’) Quantification of collagen IV levels, 
showing significant difference in collagen IV levels, where treated mice presented a 
decrease in the amount of collagen IV. Values shown as means ± S.D *p<0.05 
 Collagen IV 
A’ 
A 
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Our results suggest that Aβ, in the absence of TTR or its reduced levels, can induce 
changes in collagen IV, leading to its increase and thickening of the BM. We speculate that, 
in turn, this will prevent Aβ from being cleared and reaching the blood, further contributing 
to increased brain Aβ levels, resulting in its accumulation and aggregation in the brain. 
 
4. Isolation of brain microvessels 
Several studies in our group examined the effects of TTR in cultured brain endothelial 
cells, which have yielded important data about BBB. However, cell culture of endothelial 
cells are a very simple model, since it is known that a complex crosstalk between different 
cells from the NVU is essential for a correct development and maintenance of BBB. Thus, 
we intended to perform new studies (as mentioned in future perspectives) using brain 
microvessels, a way to use an intact BBB. For this, we tested some protocols describing 
techniques for isolating microvessels from mice brain. As observed in figure 28, structurally 
intact microvessels were successfully isolated. Samples presented cells morphologically 
Figure 28. Representation of brain microvessels obtained from mice. (A and A’) Microvessels stained 
with hematoxylin and (B and B’) showing positive staining for LRP1 (Green) and CD31 (Red). 
CD31 + LRP1 
A A’ 
B’ B 
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resembling microvessels, presenting different sizes and arrangements (isolated or in 
branches). Expression of LRP1 and CD31, characteristic proteins of vascular endothelial 
cells, was found in all microvessels. However, as seen in all images, samples presented 
relatively low purity, since a high number of microvessels are covered by adherent cells. 
Further optimization of the protocol should be done, in order to improve the microvessel 
purity of our samples. 
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The blood-brain barrier is a special membrane barrier found in the brain vessels, 
allowing a physical separation between the blood and brain. This barrier is enabled by the 
presence of an important feature between endothelial cells, the so called tight junctions. In 
addition, several other members of the neurovascular unit and the cross-talk between them 
are identified and known to be important for BBB regulation and maintenance (Abbott, 
Patabendige et al. 2010). 
Changes in the BBB are associated with the disease, which together with the 
challenge created by BBB's ability to limit access to many substances, including CNS 
therapeutic compounds, makes BBB a target for many studies (Banks 2016). In fact, several 
diseases have the disruption of the BBB as an important characteristic, such as stroke, 
Parkinson’s disease and Multiple Sclerosis (Obermeier, Daneman et al. 2013). AD, the most 
prevalent form of dementia, is another example. In AD, in addition to a decrease of tight 
junction levels, several Aβ transporters which regulate its influx and efflux are altered, 
favoring disease. RAGE, the main influx receptor of Aβ is increased, while LRP1 and P-gp, 
important efflux transporters are decrease, leading to an increase of Aβ in the brain, 
contributing for the progress of AD (Marques, Sousa et al. 2013).  
Previous studies have shown transthyretin as a neuroprotective molecule in AD, 
mainly describing its important function as an Aβ carrier, contributing to Aβ clearance at the 
BBB (Alemi, Gaiteiro et al. 2016). This is especially important, since it is thought that 
impaired Aβ clearance is one of the most important features which lead to sporadic AD, the 
large majority of AD cases. Besides its role as a neuroprotective protein in disease, recently 
studies have shown TTR as a CNS gene modulator in physiology. It was found that TTR is 
capable to promote a robust neurite outgrowth response in neurons by its interaction with 
megalin (Gomes, Nogueira et al. 2016) and also induce transcription of IGF-IR in neurons 
(Vieira, Gomes et al. 2015). In endothelial cells, TTR is also capable to increase the levels 
of LRP1 (Alemi, Gaiteiro et al. 2016), an important finding for AD pathology, since LRP1 
is decreased in this disease.  
Previous work in the lab indicated that occludin levels, decreased in the presence of 
Aβ, were normalized in cells co-incubated with Aβ and TTR, and thus we started by 
evaluating the effect of exogenous TTR in the expression of TJs-related genes, in hCMEC/D3 
cells. However, we did not observe any effect of TTR in the genes evaluated, including 
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occludin, and thus we concluded that the initial observation on the effect of TTR in occludin 
is mostly likely a reflex of the direct action of TTR in Aβ, decreasing its toxicity. It is 
important to highlight the lack of studies on this subject, not allowing us to compare the data 
obtained in our work. Nevertheless, in the future, it would be important to evaluate other 
aspects of the TJs, such as localization and structure, using techniques such as electron 
microscopy, which enable detailed studies on cellular morphology. 
With regard to TTR modulating ability, Nunes et al found that TTR regulates 
angiogenesis by conferring different molecular identities to umbilical endothelial cells 
(Nunes, de Oliveira et al. 2013), although, in their work, the authors compared the effect of 
WT TTR and V30M, without relating with the results obtained in the absence of TTR. 
Nevertheless, they found that V30M TTR decreased the expression of pro-angiogenic genes, 
as compared to the WT counterpart, in HUVEC cells. Thus, we investigated whether TTR 
variants had any modulatory function in angiogenic-related genes, VEGFR1, VEGFR2 and 
ANGPT2, using hCMEC/D3 cells, or in VEGFR1, VEGFR2 and TGFBP2 using bEnd.3 
cells. Our results revealed that TTR variants did not alter the transcript levels of any of 
analyzed genes in both hCMEC/D3 and bEnd.3 cells. Moreover, to complement our qRT-
PCR results, we evaluated endothelial cell migration, an important step of angiogenesis, 
using an in vitro wound healing assay, in the presence of WT, V30M and L55P TTR. We 
found no effect of any of the variants, nor positive, nor negative as compared to the absence 
of TTR, contrarily to Nunes and co-workers that reported V30M TTR as decreasing the 
healing capacity of HUVEC cells, compared to WT TTR. It is important to highlight that 
bEnd.3 cells or the experimental conditions used did not appear appropriated for migration 
studies in our time condition, since in our results, cells closed less than 10% of the wound 
during 10h, indicating its migration happen very slowly. Nevertheless, we expected a 
negative effect at least for the amyloidogenic variants V30M and specially the L55P. While 
V30M TTR is the most common TTR mutation in FAP patients, in Portugal, and results in 
an unstable tetramer that tends to dissociate into monomers, resulting into protein 
aggregation, accumulation and amyloid formation, L55P TTR is a very aggressive mutation, 
resulting in a very severe phenotype. FAP is a progressive, neurodegenerative disease, with 
onset in the adult life, and probably our model does not mimic these essential characteristics 
  FMUP/IBMC-I3S  91 
  Discussion  
 
 
of FAP. In an attempt to surpass this limitation, future experiments should assess the effect 
of higher TTR concentrations. 
In AD, several works report on the thickening of the BM, namely on the layer of 
collagen IV which can act as a barrier in brain vessels, preventing Aβ passage from the brain 
to the blood and therefore, also becoming responsible for Aβ accumulation (Uspenskaia, 
Liebetrau et al. 2004, Tian, Shi et al. 2006). Since TTR is involved in Aβ elimination from 
the brain, we analyzed collagen IV levels in brain vessels of AD mice with different 
backgrounds of TTR, concluding that AD/TTR+/- and AD/TTR-/- mice presented high levels 
of collagen IV surrounding brain vessels compared to AD/TTR+/+ mice. However, in our 
AD/TTR model, TTR levels were not totally inversely proportional to collagen IV levels, 
since AD/TTR-/- didn’t present higher levels of collagen than AD/TTR+/-. As explained in the 
characterization of this animal model (Oliveira, Ribeiro et al. 2011), the detrimental effects 
of the genetic reduction of TTR in AD/TTR+/- female mice are not always observed in 
AD/TTR-/- mice, such as increased levels of Formic acid- soluble Aβ42 and decreased levels 
of brain 17β-estradiol, being the later a hormone capable to induce TTR expression (Oliveira, 
Ribeiro et al. 2011). One hypothesis is that AD mice without any TTR allele might undergo 
transcriptional remodeling through which compensatory mechanisms can occur, overcoming 
the possible effects of the total lack of TTR in the pathogenesis of AD. Nevertheless, our 
results indicate that a decrease in TTR leads to an increase of collagen IV, probably indirectly 
as no differences in collagen IV were found between non-transgenic mice TTR+/+ and 
TTR+/-. We then hypothesized that high levels of Aβ, as it happens in AD, either due to 
increased production, reduced elimination or both can be responsible for the increase in 
collagen IV. Since the initial characterization of the AD/TTR model used in the current study 
showed that Aβ brain burden is also higher in AD/TTR+/- than in AD/TTR+/+, this could 
further explain the increase in collagen IV layer. Thus, TTR is acting indirectly on collagen 
IV levels, decreasing this Aβ effect, by promoting its clearance. In order to test this 
hypothesis, we performed cellular studies and showed that indeed Aβ induced increased 
collagen IV in bEnd.3 cells which was slowed down by TTR, probably by binding the peptide 
and avoiding its aggregation and accumulation. We also attempted to clarify which Aβ 
species is capable of inducing collagen IV expression, the soluble monomer, the oligomers 
and/or the fibrils. However, we failed at obtaining pure populations of each of these species, 
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as demonstrated by TEM, and all of them had a positive effect in collagen IV levels. Thus, 
in the future, it is necessary to perform the experiment with homogeneous populations of Aβ 
species, allowing to distinguish possible different effects, as it is believed that the monomer 
is non-toxic, whereas the oligomers are thought to be highly noxious to cells; as for the fibrils, 
some authors defend that they represent an off-pathway in an attempt to avoid toxicity. 
Finally, we also evaluated collagen IV levels in AD/TTR+/- IDIF-treated mice, a TTR 
tetrameric stabilizer. It is known that stabilization of TTR tetramer enhances its functions, 
such as Aβ cleavage (Ribeiro, Saraiva et al. 2012) and clearance (Alemi, Silva et al. 2017). 
We observed reduced collagen IV around brain vessels in treated mice as compared to non-
treated, indicating that, in fact, TTR stabilization is also beneficial in this TTR-related effect. 
   
 Altogether, we propose that TTR exerts a neuroprotective function in AD by cleaving 
and binding Aβ, decreasing its accumulation in the brain, and avoiding its effect in the 
increase of collagen IV, which would then lead to a consequent increase of Aβ, similar to a 
“snow-ball effect”, contributing to disease progression. Researchers believe that vascular 
alterations occur early in AD development and, therefore, TTR-based therapies are 
promising.
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Given that: 1) TTR is able to modulate some CNS genes, including genes/proteins 
that are expressed at the BBB; 2) TTR facilitates A transport across the BBB and 3) 
preliminary data indicated that TTR reversed the decrease in TJs proteins induced by A (not 
shown), we engaged a study to determine if TTR is involved, in any way, in the brain vascular 
system. 
As conclusion, we can say that TTR variants (WT, V30M and L55P), in physiological 
conditions, are 1) not capable to modulate the expression of TJs-related genes at the transcript 
and protein levels, and are 2) not involved in the regulation of angiogenesis in the brain, 
albeit 3) we confirmed its neuroprotective effect while affecting, even if indirectly, the levels 
of collagen type IV in brain vessels, thus facilitating A elimination. 
In fact, TTR had no effect on any of the TJs-related genes tested. However, our study 
was performed with a cell line and it does not mean that TTR does not modify the 
morphology of TJs, i.e. change the linkage between TJs. In the future, it would be interesting 
to address this point using isolated brain microvessels from mice with different TTR genetic 
backgrounds, allowing us to observe different intercellular tight junctions by TEM. 
Moreover, it would be important to evaluate the gene expression of other genes that presented 
a significant alteration in the PCR array. 
 In our study, it was also not possible to confirm the ability of TTR to regulate 
angiogenesis in hCMEC/D3 cells, as previously reported for HUVECs and for hRECs. 
Additional experiments should be performed before completely ruling out this hypothesis, 
such as the tube formation assay and in vivo Chick Chorioallantoic Membrane (CAM) assay 
as an in vivo tool to evaluate angiogenesis. 
Our study suggests that TTR is involved in the regulation of collagen IV levels in 
AD. Although the literature refers that the thickening of the BM can lead to A accumulation 
around brain vessels by preventing its passage to the blood, it is not clear what is the initial 
trigger. In this work, we tested the hypothesis of A as a cause for the increase in collagen 
type IV levels. However, we could not determine if only a specific A species is the 
responsible, or if even the soluble peptide can do this. Thus, homogenous preparations of 
soluble, oligomeric or fibrillar A should be obtained and tested. 
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As a follow up of this project, it is important to test if increased collagen levels indeed 
affect BBB permeability to A. To this end, permeability/transport studies should be 
performed, for instance by using hCMEC/D3 cells grown in transwell filters coated or not 
with collagen type IV and by measuring brain-to-blood A transport. Although our AD 
transgenic model established in different TTR genetic backgrounds has already been 
characterized and shown that TTR reduction results in a more severe state of disease, detailed 
localization of A accumulation in the brain was not performed. Thus, evaluation of A 
localization and levels in brain vessels in these mice should be performed to correlate 
TTR/A/collagen type IV levels. Moreover, and aiming at understanding which is cause and 
effect, evaluation of A and collagen type IV levels in vessels should be performed in animals 
of different ages, before, at and after disease onset. Finally, isolated brain microvessels (after 
further optimization of the current protocol) might constitute an alternative model to measure 
the thickness of the basal membrane and to investigate the effects of A and TTR, as well as 
other factors. 
Alterations in the brain vasculature are thought to occur very early in AD and thus 
this work highlights the potential of TTR as neuroprotective protein and as a therapeutic 
target. 
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